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Chapter 1 
Introduction 
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Extended release drug therapy 
            For many decades treatment of acute diseases or chronic illnesses have 
been mostly accomplished by delivery of drugs to patients using various 
pharmaceutical dosage forms including tablets, capsules, suppositories, creams, 
ointments, liquids, aerosols and  injectables. Even today these conventional dosage 
forms are the primary pharmaceutical vehicles commonly seen in the prescription 
and over the counter drug market. The oral conventional types of drug delivery 
systems are known to provide a prompt release of the drug. Therefore to achieve as 
well as to maintain the drug concentration within the therapeutically effective range 
needed for treatment, it is often necessary to take this type of drug delivery system 
several times a day. This results in a significant fluctuation in drug levels often with 
a sub-therapeutic and or toxic levels and wastage of drug. Recently several technical 
advancements have resulted in the development of new systems of drug delivery 
capable of controlling the rate of drug delivery, sustaining the duration of 
therapeutic activity and targeting the delivery of drug to a tissue
1
.  
 The term controlled/extended release implies a system that provides 
continuous delivery of the drug for a predetermined period with predictable and 
reproducible kinetics and a known mechanism of release. This means that the release 
of drug  from a controlled release drug delivery system proceeds at a rate that is not 
only predictable  kinetically but also reproducible from one unit to another. In other 
words, the system attempts to control drug concentration in the target tissue.   
 The oral route of administration for extended release systems has received 
greater attention because of more flexibility in dosage form design. The design of 
oral extended release delivery systems is subjected to several interrelated variables 
of considerable importance such as type of delivery system, the disease being 
treated, the patient, the length of therapy and the properties of the drug. 
        Extended release 
2
denotes that the system is able to provide some actual 
therapeutic control whether be it of temporal or spatial nature or both. In other 
words, the system attempts to provide a constant drug concentration in the target 
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tissue. It is this nature of this system that makes it different from sustained release 
systems. 
1.1  Advantages of extended release dosage form:
 3
 
 Improved patient compliance and convenience due to less 
frequent drug administration. 
 Reduction in fluctuation in steady state levels and therefore, better 
control of disease condition and reduction intensity of local or 
systemic side effects. 
 Increased safety margin of high potency drugs due to better 
control of plasma levels. 
 Maximum utilization of drug enabling reduction in total amount 
of dose administered. 
 Reduction in health care costs through improved therapy, shorter 
treatment period, less frequent dosing and reduction in personnel 
time to dispense, administer and monitor patients. 
 Sustained blood levels; the size and frequency of dosing are 
determined by the pharmacokinetic and pharmacodynamic property 
of drug. The use of extended release products may maintain 
therapeutic concentration over prolonged period. 
 Attenuation of adverse effect, the use of extended release products 
avoids the high initial   blood concentration, which may cause many 
side effects like nausea, local irritation, haemodynamic changes etc.                                                                                                                                                                                                                 
1.2  Disadvantages of extended release dosage for:
 3 
 
 Toxicity due to dose dumping. 
 Increased cost. 
 3 
 
 
 Unpredictable and often poor in vitro- in vivo correlation. 
 Risk of side effects or toxicity upon fast release of contained drug 
(mechanical failure, chewing or masticating, alcohol intake). 
 Local irritation or damage of epithelial lining (lodging of dosage 
forms). 
 Need for additional patient education and counseling. 
 Increased potential for first- pass clearance. 
1.3  Ideal candidate for extended/controlled release drug delivery systems: 
4-6 
               The desired biopharmaceutical characteristics of drugs to be used in the 
development    of per oral controlled release dosage forms are:  
 Molecular weight :  <1000 mg 
 Solubility              :  0.1mcg/ml 
           P
ka                                           
:  >0.1% to 1% at pH 1 to 7.8 
 Apparent partition coefficient   :  0.5 to 2.0 
 General absorbability :  From all GI segment 
 Stability :  Stable in GI environment 
Release should not be influenced by pH and   enzymes. 
Less protein binding. 
 To evaluate whether a drug is viable candidate or not for the design of per 
oral CR formulation, one must consider the following pharmacokinetic parameters 
of the drug.  
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 Elimination half-life             :      Preferably between 0.5& 8 hours 
    Total body clearance              :      Should not be dose dependent 
   Elimination – rate constant   :      Required for the design 
    Absolute bioavailability         :      Should be 75% or more 
    Absorption rate :     Must be greater than release rate 
Therapeutic concentration   :                                        
 The lower the css
av
 and the smaller the vd the lesser is the amount required.                                                                           
Apparent volume of distribution (Vd): 
           The larger the vd and Minimum Effective Concentration (MEC), the 
larger will be the dose size required. The maximum dose to be incorporated in to a 
per oral Controlled release (CR) formulations is about 500mg. The smaller the vd , 
the easier is incorporation of drug in to dosage form.  
Minimum toxic concentration (MTC):                
         MTC and MEC, the further apart these t values are, the safer the dosage 
and also suitable for drugs with very short t
1/2.
 
1.4    Unsuitable candidates for extended-Release dosage forms: 
7
   
 Short elimination biological half-life      
 E.g. Penicillin G, Furosemide   
 Long elimination biological half life (>12hr)    
       E.g. Diazepam, Phenytoin 
 Narrow therapeutic index         
 E.g.  Phenobarbital, Digitoxin. 
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 Not effectively absorbed in the lower intestine.                                                 
E.g.  Riboflavin, Ferrous salts.  
 Large doses (>1g): 
  E.g, Sulphonamides. 
1.5    Controlled Release Formulations:
 8
 
1.5.1  Types of Controlled Release Systems  
Matrix type tablets  
 Hydrophobic & hydrophilic matrices. 
 Plastic matrices 
 Ion exchange resins 
 Co-precipitates & solid dispersions. 
Film-Coating Tablets 
 Diffusion-controlled membrane  
 Osmotic pumps 
 Floating Tablets  
 Swellable Tablets  
 Mucoadhesive Tablets 
 Complexation 
 Cyclodextrins 
 Pharmaceutical adhesives. 
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3)  Multiple-Unit Tablets 
II Capsules 
1) Hard capsules 
2) Soft elastic capsules 
3) Floating capsules 
III Micro granules/spheroids 
IV Beads 
V  Pellets 
 VI Emulsions 
VII Suspensions 
VIII Liposomes 
IX Micorparticles 
X Nano particles 
1.6  Matrix Systems: 9 
Definition: 
       Matrix formulations are defined as a drug or other active ingredient 
embedded in insoluble excipient in order to achieve release by a continuous leaching 
of the drug from the inert matrix core. 
1.6.1  Matrix Tablets: 
       These are the simplest & least expensive systems for controlled drug 
delivery. Their processing is reproducible & is similar to that conventional system. 
The polymer or other carrier is homogeneously mixed with drug. 
 7 
 
 
Drug release from the bulk of matrix involves two matrix mechanisms: 
1) The Erosion rate of the matrix determines the drug release state in 
matrices governed by erosion or dissolution 
                                                      eq         (1)                                    
                   
Where: 
  - Drug release rate. 
            S - Surface area 
         - Matrix erosion rate 
         - Drug Concentration gradient 
2)  The diffusion through a barrier membrane describes drug release in 
  insoluble coating via fick‘s second law of diffusion. 
                                                          eq         (2) 
Where: 
 D – Diffusion coefficient 
       S – Exposed surface area 
     K –Partition coefficient 
       – Drug concentration gradient 
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1.6.2  Advantages of matrix system 
         Unlike reservoir and osmotic systems, products based on matrix design 
can be manufactured using conventional processes and equipments. Secondly, 
development cost and time associated with the matrix system generally are viewed 
as variables, and no additional capital investment is required. Lastly, a matrix system 
is capable of accommodating both low and high drug loading and active ingredients 
with a wide range of physical and chemical properties. 
1.6.3  Limitations of the matrix systems 
       As with any technology, matrix systems come with certain limitations. 
First, matrix systems lack flexibility in adjusting to constantly changing dosage 
levels as required by clinical study outcome. When new dosage strength is deemed 
necessary, more often than not a new formulation and thus additional resources are 
expected. Furthermore, for some products that require unique release profiles (dual 
release or delayed plus extended release), more complex matrix-based technologies 
such as layered tablets are required. 
1.6.4.  Types of matrix systems 
                  The matrix system can be divided into two categories depending on the 
types of retarding agent or polymeric materials. 
1.6.4.1  Hydrophobic matrix system 
                 This is the only system where the use of polymer is not essential to 
provide controlled drug release, although insoluble polymers have been used. As the 
term suggests, the primary rate-controlling components of hydrophobic matrix are 
water insoluble in nature. These ingredients include waxes, glycerides, fatty acids, 
and polymeric materials such as ethyl cellulose, methyl cellulose and acrylate 
copolymer. To modulate drug release, it may be necessary to incorporate soluble 
ingredients such as lactose into formulation. The presence of insoluble ingredient in 
the formulations helps to maintain the physical dimension of hydrophobic matrix 
 9 
 
 
during drug release. As such, diffusion of active ingredient from the system is the 
release mechanism, and the corresponding release characteristic can be described by 
Higuchi equation known as square root of time release kinetic
9
. The square root of 
time release profile is expected with a porous monolith, where the release from such 
system is proportional to the drug loading. In addition, hydrophobic matrix systems 
generally are not suitable for insoluble drug because the concentration gradient is 
too low to render adequate drug release. As such, depending on actual ingredient 
properties or formulation design, incomplete drug release within the gastrointestinal 
transit time is a potential risk and need to be delineated during the development. 
With the growing needs for optimization of therapy, matrix systems providing 
programmable rates of delivery become more important. Constant rate delivery 
always has been one of the primary targets of controlled release system especially 
for drug with narrow therapeutic. 
1.6.4.2    Hydrophilic matrix system 
 The primary rate limiting ingredients of hydrophilic matrix are polymers 
that would swell on contact with aqueous solution and form a gel layer on the 
surface of the system. When the release medium (i.e. water) is thermodynamically 
compatible with a polymer, the solvent penetrates into the free spaces between 
macromolecular chains. The polymer may undergo a relaxation process, due to the 
stress of the penetrated solvent, so that the polymer chains become more flexible and 
the matrix swells. This allows the encapsulated drug to diffuse more rapidly out of 
the matrix. On the other hand, it would take more time for drug to diffuse out of the 
matrix since the diffusion path is lengthened by matrix swelling. Moreover, it has 
been widely known that swelling and diffusion are not the only factors that 
determine the rate of drug release. For dissolvable polymer matrix, polymer 
dissolution is another important mechanism that can modulate the drug delivery rate. 
While either swelling or dissolution can be the predominant factor for a specific type 
of polymers, in most cases drug release kinetics is a result of a combination of these 
two mechanisms. The presence of water decreases the glassy-rubbery temperature 
(for HPMC from 184°C to below 37°C), giving rise to transformation of glassy 
polymer to rubbery phase (gel layer). The enhanced motility of the polymeric chain 
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favours the transport of dissolved drug. Polymer relaxation phenomena determine 
the swelling or volume increase of the matrix, Boniferoni et al. (1995) showed a 
relationship between rheological behavior of HPMC gels and their erosion rate, 
conforming that the polymer-polymer and polymer-water interaction are responsible 
for the gel network structure and its sensitivity to erosion. In turn, they affect drug 
release rate in the case of poorly soluble drugs
10
. 
         Swelling controlled release systems are based upon these principles. Due 
to the viscoelastic properties of the polymer which are enhanced by the presence of 
cross-linked network, anomalous penetrant transport can be observed. This behavior 
is bound by pure Fickian diffusion and case II transport. Therefore, transport can be 
reduced to three driving forces. The penetrant concentration gradient, polymer 
concentration gradient and osmotic force behavior are observed as a result of 
polymer network. Appropriate polymer can counterbalance normal Fickian diffusion 
by hindering the release of embedded drug, leading to an extended period of drug 
delivery, and possibly zero-order release. 
        Drug release from swellable matrix tablets can be affected by glassy-
rubbery transition of polymer (as a result of water penetration into the matrix where 
interaction among water, polymer and drug or fillers is considered as the primary 
factor for release control) and the various formulation variables, such as polymer 
grade and type, drug to polymer ratios, drug solubility, drug and polymer particle 
sizes, compaction pressure and presence of additives recipients in the final 
formulation
9
. 
1.6.5  Materials used as Retardants in matrix Tablets:
 11 
 
 Various polymers have been investigated as drug retarding agents, each 
presenting a different approach to the matrix system. Based on the features of 
retarding polymer, matrix systems are usually classified into three main groups. 
They are: 
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Table: 1   Materials used as retardants in matrix Tablets 
Nature of the polymer Examples 
Insoluble, Inert 
 
Poly Ethylene, Polyvinylchloride, Ethyl cellulose 
and Methyl acrylate 
Insoluble, Erodible 
 
Carnaubawax, Stearyl alcohol ,Stearic acid 
PolyEthyleneglycol, and Triglycerides. 
Hydrophilic 
Methyl cellulose ,Hydroxy Ethyl cellulose 
Hydroxy propyl Methylcellulose, Xanthangum, 
Sodium alginate,and Chitosan. 
 
1.6.6.   Methods of preparation:
 12                  
 Three methods may be used to disperse drug and additives in a retardant 
base. 
 Solvent evaporation technique   
              In this technique a solution or dispersion of a drug and additive is 
incorporated into molten wax phase and the solvent is removed by evaporation. 
 Compression technique  
            This involves the compression of granules, which may be prepared by wet 
granulation or dry granulation technique or direct compression of blend of drug, 
release retardant material and other additives.  
 Fusion technique 
           Drug and additives are blended into the molten wax matrix at a 
temperature slightly above melting point more uniform dispersion can be obtained 
by this technique. 
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1.7    Drug Release from Matrix Systems 
1.7.1.  Mechanism of drug release from swelling controlled release systems 
1.7.1.1  Polymer swelling and drug release 
         The overall drug release mechanism from swelling controlled release 
systems based pharmaceutical devices strongly depends on the design (composition 
and geometry) of the particular delivery system. When a matrix comes in contact 
with an aqueous solution, wetting occurs first at the surface and then progresses by 
way of microscopic pore spaces into the matrix. The excipient in the matrix also 
absorb water, hydrates and swells to block up the existing pores, dissolves the 
content to create a more porous structure, gels to form a more viscous solution 
giving rise to positive pressure opposing liquid entry or causes disintegration of the 
matrix . Before a liquid can enter a matrix, there must be a driving force, which is 
derived from the pressure difference. The rate of liquid penetration into the matrix is 
determined by balance of this force promoting fluid entry towards the interior and 
the viscous force opposing it, which soon develops as soluble excipients in matrix 
dissolve or swell
13
. The swelling of the matrix and consequent drug release by 
diffusion from the matrix and erosion of the matrix is shown in Figure 1a and 1b. 
          
 
 
 
 
 
Fig: 1 (a) Drug release controlled by polymer erosion; (b) Drug release 
controlled by swelling and erosion
14.
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 A hydrophilic matrix, controlled-release system is a dynamic one 
involving polymer wetting, polymer hydration, gel formation, swelling, and polymer 
dissolution. At the same time, other soluble excipients or drugs will also wet, 
dissolve, and diffuse out of the matrix while insoluble materials will be held in place 
until the surrounding polymer/excipient/drug complex erodes or dissolves away. The 
mechanisms by which drug release is controlled in matrix tablets are dependent on 
many variables. The main principle is that the water-soluble polymer, present 
throughout the tablet, hydrates on the   outer tablet surface to form a gel layer (Fig: 
2). Throughout the life of the ingested tablet, the rate of drug release is determined 
by diffusion (if soluble) through the gel and by the rate of tablet erosion
14
. 
 
Fig: 2 Mechanism of drug release from matrix gel forming tablets 
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A detailed description of the swelling, erosion and drug release process 
can be described as follows: 
(i) At the beginning of the process, steep water concentration 
gradients are formed at the polymer water interface resulting in 
water imbibation into the matrix. In dry systems the diffusion 
coefficient is very low, whereas in highly swollen gels it is of the 
same order of magnitude as pure water. Water acts as a plasticizer 
and reduces the glass transition temperature (Tg) of the system. 
Once the Tg equals the temperature of the system, polymer chains 
undergo the transition from the glassy to the rubbery state as 
shown in (Fig: 3)
15
. The glass transition temperature Tg, of a 
polymer is an important characteristic constant, in particular with 
respect to applications in the field of controlled drug delivery. 
Below the Tg the mobility of the macromolecules is very low. The 
material is in its glassy state resulting in extremely small diffusion.  
(ii) In contrast, above the glass transition temperature the mobility of 
the polymer chains is markedly increased (rubbery state), leading 
to much higher mass transfer rates of water and drug. For instance 
Tg for HPMC is reported to be 154 to 184
o
C
15
. 
 
Fig: 3 Drug concentration profile as a function of glass and rubbery regions
16
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(iii)   The imbibitions of water and formation of rubbery region; which 
externally appears as polymer swelling results in dramatic changes 
of polymer and drug concentrations, and increasing dimensions of 
the system. The polymer chains unfold, and gradually become 
solvated, voids created as the polymer unfolds is occupied by water 
molecules. The apparent volume occupied by these expanded coils 
is referred to as the hydrodynamic volume. 
                         
  Fig: 4 Different front positions observed during matrix swelling and erosion
17
 
(iv)   Upon contact with water the drug dissolves and (due to 
concentration gradient) diffuses out of the device.  Three fronts are 
observed as shown in (Fig: 4) The Swelling front, identifying the 
boundary between the still glass polymer and its rubbery gel state. 
The boundary between the still undissolved (solid) drug and the 
dissolved drug in the gel layer is indicated by diffusion front and 
erosion front identifies the boundary between matrix and 
dissolution medium. Gao et al. (1996) studied the swelling 
behavior of HPMC matrices using Adinazolam mesylate as the 
model drug, and concluded that swelling is anisotropic with 
preferential expansion in the axial direction; swelling is isotropic 
with respect to the gel layer thickness and composition in both 
axial and radial directions
17
. 
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Fig 5: Gel layer thickness as a function of time 
(v) With increasing water content the diffusion coefficient of the drug 
increases substantially. It is to be noted that during drug delivery, 
as swelling and dissolution of the polymer compete, the gel layer 
thickness first increases due to swelling (Region a in Fig: 5), then 
remains constant due to synchronization of swelling, drug 
diffusion, and dissolution (Region b) and finally decreases (Region 
c) as dissolution takes over.  
 Thus finally the release of drug is complete as the matrix erodes. The drug 
release from a swelling matrix system thus can be summed up to be governed by 
drug diffusion through the matrix and polymer erosion. It is to be noted that in the 
case of poor water-solubility, dissolved and undissolved drug coexist within the 
polymer matrix. Undissolved drug is not available for diffusion. In the case of high 
initial drug loadings, the inner structure of the matrix changes significantly during 
drug release, becoming more porous and less restrictive for diffusion upon drug 
depletion. Depending on the chain length and degree of substitution of the HPMC 
type used, the polymer itself dissolves more or less rapidly (erosion of the polymer).  
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1.7.1.2    Polymer erosion
18
 
 Polymer chain dissolution from the matrix involves two distinguishable 
processes as depicted in (Fig: 6). 
 The first step involves disentanglement of the individual molecules 
at matrix surface, which depend on rate of hydration. This occurs 
at a critical polymer concentration, defined as ‗polymer 
disentanglement concentration. This polymer concentration 
depends on properties of the polymer and solvent. 
 The second step involves the transport of these molecules from the 
surface across an aqueous diffusion layer, adjacent to the matrix, to 
the bulk solution
19
. 
 
Fig 6: A system showing polymer erosion, (a) initial polymer entanglement 
in the matrix, (b) repeating chain disentangling from the system and 
(c) finally disentangling from the system. 
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1.7.2  Regulatory considerations in extended release products:
 19
   
 The bioavailability data requirement as specified by FDA for the 
controlled release products are: The drug product meets the 
controlled release claims made for it. 
 The bioavailability profile established for the drug product rules 
out the possibility of any dose dumping. 
 The drug product‘s steady-state performance is equivalent to a 
currently marketed non-controlled release or controlled release 
drug product with the same active ingredient or therapeutic moiety, 
which has been subjected to an approved full new drug application. 
 The drug product‘s formulation provides consistent pharmaco-
kinetic performance between administrations. 
 The reference standard for comparative studies should include one 
of the following. 
1.8 Pharmaceutical coating processes:
20-23
 
 Basically  there  are  five  major  techniques  for  applying  coatings  to  
pharmaceutical solid  dosage  forms:  
1.  Sugar coating 
2.  Film coating 
3.  Enteric coating 
4.  Fluid bed or suspension coating 
5.  Compression coating 
 
 19 
 
 
        The present formulation involves enteric coating to protect the   drug   in 
the stomach from degradation, which makes the formulation delayed release. Hence 
the detailed explanation is given on enteric- coating.  
1.8.1  Enteric Coating:
 21
 
           Enteric coating is a barrier applied to oral medication that controls the 
location in the GIT region, where it is absorbed.  Enteric refers to the small intestine, 
therefore enteric coatings will dissolve in intestine and prevent release of medication 
before it reaches small intestine and give desired pharmacological action. The prime 
intension is to delay the release of drugs which were inactivated by the stomach 
contents or may cause nausea or bleeding by irritation of gastric mucosa.
 
Significance of Enteric coating: 
 To protect acid-labile drugs from the gastric fluid. 
 To protect from gastric distress or nausea due to irritation of the 
drug. 
 To deliver drugs intended for local action in the intestine. 
 To deliver drug that are optimally absorbed in the small intestine to 
their primary absorption site in their most concentrated form. 
 To provide a delayed release component to repeat actions. 
 Protect the drugs from harmful effect of the gastric contents     
because  some of the drugs are prone to be hydrolyzed in acid 
media (Eg. Rabeprazole sodium, Esomeprazole, Omeprazole, 
Oxybutynin chloride). 
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1.8.2   Enteric Coating Polymers:
 22
 
     Enteric coatings are usually formulated with synthetic polymers that 
contain ionisable functional groups that render the polymer water soluble at a pH 
value.  Since many of these enteric polymers are esters, they may be subject to 
degradation (as a result of hydrolysis) when exposed to conditions of elevated 
temperature and humidity; such hydrolysis can result in a substantial change in 
enteric properties. 
Properties of an Ideal enteric coating polymer: 
1.  Resistance to gastric fluids. 
2.  Ready susceptibility to or permeability to intestinal fluids. 
3.  Compatibility with most coating solution components and the drug 
substrates. 
4.  The film should not change on aging. 
5.  Formation of continuous film. 
6.  Non-toxicity. 
7.  Low cost. 
8.  Ease of application 
              A polymer with threshold pH in the range of 5 to 6 is considered ideal for 
an enteric coat. This is based on the premises that the pH of the stomach, even in the 
fed state, will rarely reach this level but will exceed duodenum, where secretion of 
bicarbonate neutralize the acidic chyme, leaving the stomach. There is no single 
polymer that applicable for the enteric coating all drug molecules. The nature of core 
materials (acidity, basicity or permeability through different enteric polymer films) 
may limit the choice of polymer. 
 21 
 
 
 Cracking of the film either during application or on storage will result in a 
loss of enteric properties. Therefore, consideration must be given to the mechanical 
properties of the applied film. Cracking problems can be effectively overcome by 
plasticization. Plasticizer can also be used to reduce the permeability of the polymer 
films to water vapor.  
            The choice of suitable plasticizer is restricted to non-water soluble 
materials because these are likely to be most effective. 
 General rule to follow is to use 1 part plasticizer to 10 parts polymer. One 
should also considered viscosity of the plasticizer, its influence on the final coating 
solution, its effect on film permeability, tackiness, flexibility, solubility, taste, 
toxicity, compatibility with other coating solution components, stability of the film 
and the final coated product. 
Most enteric coatings won't dissolve in solutions with a pH lower than 5.5.  
Commonly-used enteric coating polymers: 
1. Methacrylic acid copolymers. 
2.  Cellulose acetate (and its succinate and phthalate version). 
3.  Hydroxy propyl methyl cellulose phthalate. 
4.  Polyvinyl acetate phthalate. 
5.  Hydroxy ethyl ethyl cellulose phthalate. 
6.  Cellulose acetate tetrahydrophtalate. 
7. Acrylic resin. 
8.  Shellac. 
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1.8.3 Film Coating of Solid Dosage forms:
 23
 
           Film coating is a process that involves the deposition of thin but uniform, 
polymer film onto the surface of the core tablet. Unlike sugar coating, the flexibility 
afforded in film coating allows additional substrates, other than just compressed 
tablets, to be considered for coating (e.g. powder, granules, nonpareils, capsules). 
Coatings are applied continuously to moving bed of material usually by means of a 
spraying technique, although manual application procedures have been used. 
Historically, film coating was introduced in the early 1950 to combat the 
shortcomings of the then predominant sugarcoating process. Film coating has proved 
successful as a result of the many advantages offered which includes,  
 Minimal weight increase (typical 2 to 3% of tablet core weight) 
 Significant reduction in processing times 
 Increased process efficiency and output 
 Increased flexibility in formulation 
 Improved resistance to chipping of the coating 
 Cost effectiveness 
 Acceptable  for diabetic patients     
1.8.4 Other additives:
 23
 
1.8.5 Plasticizer 
         Plasticizers can modify the physical and chemical properties of the 
polymers. Optimization of plasticizer must be concentration based on presence of 
other additives. Some of the commonly used plasticizers are castor oil, 
propyleneglycol, polysorbates and organic acid   esters. 
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1.8.6. Colorants 
          Colorants are used to provide distinctive color and elegance to a dosage 
form. The most common colorants in use are certified food drug and cosmetics 
colorants. These are synthetic dyes or lakes of dyes. 
1.8.7 Solvents 
          The primary function of a solvent system is to dissolve or disperse the 
polymers and other additives and convey them to the substrate surface. The most 
widely used solvents for enteric coating polymers are water, ethanol, isopropanol, 
chloroform, acetone etc. 
1.9   Disease etiology  
        Urinary incontinence:
 24, 25
 
  An overactive bladder is a condition that results from involuntary 
contraction of the muscle in the wall of the urinary bladder. Overactive bladder 
causes a sudden and unstoppable need to urinate (urinary urgency). Overactive 
bladder is also referred to as urge incontinence and is a form of urinary incontinence 
(unintentional loss of urine).  
 Over reactive bladder increases with age approximately more than 65 
years and is reported that 5% to 10% of the adult populations and its prevalence 
increases with age affected by this disorder worldwide, which has impaired quality 
of life of patients. Antispasmodics are the drugs of choice in treatment of urinary 
incontinence. Overactive bladder affects an estimated 1 in 11 adults in the United 
States. Overactive bladder, however, should not be considered a normal part of 
aging.  
 The symptoms of overactive bladder include frequent urination, urgency  
of urination, and urge incontinence. Overactive bladder may cause significant social, 
psychological, occupational, domestic, physical, and sexual problems. This 
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Involuntary loss of urine is reportedly experienced by upwards of 95% of women in 
their reproductive and post-menopausal years.   
1.9.1    Types of urinary incontinence 
 Stress Incontinence  
 Urine leakage occurs with increases in abdominal pressure (hence, 
mechanical ―stress‖).  
 Urge Incontinence 
 Often referred to as ―overactive bladder.‖ Inability to hold urine long 
enough to reach restroom.  
 Mixed Incontinence 
 When two or more causes contribute to urinary incontinence. Often refers 
to the presence of both stress and urge incontinence.  
 Overflow Incontinence 
 Leakage or ―spill-over‖ of urine when the quantity of urine exceeds the 
bladder‘s capacity to hold it.  
 Functional Incontinence 
 Leakage (usually resulting from one or more causes) due to factors 
impairing reaching the restroom in time because of physical conditions (e.g., 
arthritis)  
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1.9.2 Medications that Can Cause Urinary incontinence:
 25
 
Table: 2 Medications that Can Cause Urinary incontinence. 
Medication Effect On Lower Urinary Tract 
Diuretics Diuresis induced by diuretics may precipitate 
incontinence. This is particularly relevant in older 
persons and/or in those with already impaired 
continence. 
Calciumchannel 
blockers (heart & blood 
pressure medications) 
Calcium channel blockers can reduce smooth 
muscle contractility in the bladder and occasionally 
can cause urinary retention and overflow 
incontinence 
[[ 
1.9.3 Medications 
Drugs commonly used to treat incontinence include: 
 Anticholinergics:  These prescription medications calm an overactive 
bladder, so they may be helpful for urge incontinence. Several drugs fall under this 
category, including oxybutynin (Ditropan), tolterodine (Detrol), darifenacin 
(Enablex), fesoterodine (Toviaz), solifenacin (Vesicare) and trospium (Sanctura). 
Possible side effects of these medications include dry mouth, constipation, blurred 
vision and flushing. 
 Topical estrogen:   Applying low-dose, topical estrogen in the form of a 
vaginal cream, ring or patch may help tone and rejuvenate tissues in the urethra and 
vaginal areas. This may reduce some of the symptoms of incontinence. 
 Imipramine:   Imipramine (Tofranil) is a tricyclic antidepressant that 
may be used to treat mixed — urge and stress — incontinence. 
 Duloxetine:  The antidepressant medication duloxetine (Cymbalta) is 
sometimes used to treat stress incontinence. 
 
  
 
Chapter 2 
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 Pritam et al., (2007)26 designed a porous osmotic pump for the 
release of oxybutynin, containing pore-forming water-soluble additives 
in the coating membrane which, when comes in contact with water 
dissolves and forms microporous structure. The effect of different 
formulation variables such as ratio of drug to osmogent, membrane 
weight gain, and level of pore former on the in-vitro release was 
studied. It was observed that the rate of drug release was increased with 
increase in the amount of osmogent because of the increased water up 
take which is the driving force for the drug release. The release of 
oxybutynin was inversely proportional to the membrane weight gain. 
The mechanism of drug release was found to be zero-order kinetics. 
 Raslamol K et al., (2010)27 studied the release of oxybutynin 
chloride from matrix tablets, using different concentrations of polymers 
(HPMC, EC, PVP, METHOCEL K100) formulated by wet granulation 
technique. The prepared formulations were evaluated for the release of 
drug, along with usual physical parameters, and were observed that the 
formulation containing Methocel K100M shown the release similar to 
that of marketed tablet. The release of drug was maximum in zero-
order, and the mechanism of drug release was observed to be following 
Korsmeyer-Peppas model.  
 P santi et al., (2006)28     prepared transdermal films by dissolving in 
water an adhesive (plastoid), a film former (polyvinyl alcohol), a 
plasticizer (sorbitol), and the oxybutynin Hydrochloride. Permeation 
experiments were conducted in Franz-type diffusion cells using rabbit 
ear skin as barrier .the release profiles showed much higher release in 
occlusive conditions than in non-occlusive condition. 
 Gayatri Sathyan et al.,(2001)29  compared the dry mouth a common 
side-effect observed with immediate-release oxybutynin,and a controlled-
release formulation of oxybutyninchloride, is a once-daily oral dosage 
form that incorporates the OROS technology.The steady state 
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stereospeci®c pharmacokinetics were alsoestablished for the two 
formulations and the kinetic-dynamic relationship ofoxybutynin was 
examined.by a  randomized, repeated-dose, double-blind, two-
treatment, two period crossover study,with frequent sampling on day 4 
to analyse for plasma  R- and S-desethyloxybutynin concentrations.the 
study concluded that Oxy-XL maintains relatively constant plasma drug 
and metaboliteconcentrations and minimizes frst-pass metabolism of 
oxybutynin. The metaboliteappears to contribute to dry mouth 
associated with oxybutynin, and following Oxy-XL metabolite exposure 
is reduced compared with IR-Oxy. Consequently less dry mouth was 
observed with Oxy-XL as compared with IR-Oxybutynin . 
  Marvin M Goldenberg et al., (1999)30   designed an extended-
release oral table formulation, OROS oxybutynin which uses 
osmotic pressure to deliver the drug at controlled rate. The 
formulation contains a two-part core consisting of a drug layer and 
―push‖ layer containing osmotically active components surrounded 
by a semipermiable membrane with a laser drilled opening. As the 
water in the gastro intestinal tract enters the tablet the push layer 
expands and pushes the drug out into the gastro intestinal tract 
through the orifice. The pharmacokinetic studies have indicated a 
slow rise in mean plasma concentration 4 to 6 hours after a single 
dose of OROS followed by maintenance dose of steady 
concentrations for 24 hours. The efficacy was compared with 
immediate release formulation showed no adverse effects. 
  Shivanand Pandey et al.,(2009)31 developed a  porous osmotic 
pump  of Oxybutynin containing pore-forming water-soluble 
additives in the coating membrane, which after coming in contact 
with water, dissolved, resulting in the formation of a microporous 
structure. The effect of different formulation variables, namely, 
ratio of drug to osmogent, membrane weight gain, and level of 
pore former on the in vitro release was studied. The release was 
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inversely proportional to the membrane weight gain; however, 
directly related to the level of pore former, sorbitol, in the 
membrane. This system was found to deliver oxybutynin at a zero-
order rate. 
  Roger R. Dmochowski et al.,(2006)32   had developed the 
transcutenaous delivery of Oxybutynin maintaining the efficacy of 
oral oxybutynin while significantly minimizing side effects (e.g., 
dry mouth). By avoiding hepatic and gastrointestinal metabolism 
of oxybutynin, less N-desethyloxybutynin ( N-DEO) is produced 
and this compound is deemed to be responsible for anticholinergic 
side effects such as dry mouth. This novel oxybutynin formulation 
offers patients with OAB and urge urinary incontinence a well-
tolerated option for managing the symptoms of overactive bladder. 
  Subhash Chandra Bose P et al.,(2011)33  formulated  transdermal 
patches of  Oxybutynin HCl using HPMCK4M, Chitosan, 
HPMCP, PVP and PVA. FTIR and DSC studies revealed that there 
was no interaction b etween Oxybutynin HCl and polymers. Gas 
phase chromatography was carried to estimate the residual 
Methanol, acetic acid and dichloromethane. The patches were 
evaluated for their thickness, folding endurance, weight 
uniformity, content uniformity, swelling behaviour, tensile 
strength, and surface pH. The tensile strength was found higher for 
formulations containing HPMCP and HPMCK4M. In vitro release 
studies was carried out in 6.6 pH phosphate shown, Patches 
containing chitosan and HPMCK4M exhibited greater release than 
the HPMCP, PVP, PVA and HPMCK4M.T he  drug release was  
in the range of 63.8 to 99.9% at 8 hrs. Many of the buccoadhesive 
systems followed zero-order release kinetics, concluding that 
buccoadhesive patches of Oxybutynin HCl can be developed as 
potential controlled release formulations for the treatment of 
hypertension. 
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  David R Staskin et al.,(2009)34 designed a OTG(oxybutynin 
topical gel)  to provide consistent plasma  levels with daily 
application, favorably altering the circulating N-
desethyloxybutynin metabolite:oxybutynin ratio, and to utilize a 
biocompatible delivery system, thus minimizing both the 
anticholinergic adverse effects of oral formulations and the 
application-site skin reactions associated with other forms of 
transdermal delivery.  Oxybutynin topical gel shows efficacious, 
safe, and convenient alternative to other oxybutynin formulations 
and other oral anticholinergic medications for the treatment of 
Over reactive urinary bladder.  
  Bajaj et al., (2008)36 prepared a novel metered dose Transdermal 
Spray formulation for Oxybutynin, and the release from a series of 
ethanol/acetone/methylal based formulations were assessed in 
vitro and the developed formulation was used for delivery from a 
metered dose spray. Various parameters like spray pattern, particle 
size distribution, pH, evaporation time, pump seal efficiency test, 
average weight per metered dose, content per spray and content    
uniformity were evaluated. Different film forming agents were 
assessed and carbopol (0.5%) and lutrol (0.1%) were found to give 
good clarity of solution, evaporation rate, spray pattern and 
tackiness of the film. Diffusion studies of the optimized 
formulations through the semipermeable membrane showed the 
release of drug to the extent of almost 50% over a period of 24 h. It 
was concluded that the results obtained shown that the metered 
dose transdermal spray formulation is a promising and innovative 
therapeutic system for the administration of oxybutynin. 
  A.D.Woolfson  et al.,(2003)36  designed a reservoir device  of an  
itravaginal  ring containing oxybutynin  silicone elastomer core 
encased in a non-medicated silicone sheath, manufactured by 
reaction injection moulding at 50˚C. An unusually high initial burst 
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release of oxybutynin was observed in vitro with a full length core 
(100 mg drug loading), with subsequent non-zero order drug 
release. Use of fractional segment cores substantially reduced the 
burst effect, yielding linear cumulative drug release versus time 
plots from days 2 to 14. Thus, a 1/8 fractional segmentcore gave a 
24 h burst of 11.28 mg oxybutynin and, thereafter, zero order 
release at the target dose of 5 mg/day over 14days. Two 
oxybutynin cores, each 1/16 of full length, gave a greater release 
than a single 1/8 core, due to core segment endeffects resulting in 
an increased surface area for release. The burst release was 
investigated by determining drug solubilities in the propan-1-ol 
product of elastomer condensation cure (390 mg/ml) and in the 
elastomer itself (13.9–20.21 mg/ ml, bydirect extraction and 
indirect thermal methods). The high oxybutynin solubilities were 
considered the major contributors to the burst effect. It was 
concluded that use of a fractional segment core would allow 
development of a suitable oxybutynin reservoir IVR. 
  Ranjini V Nellore et al.,(1998)37  developed extended release 
matrix Table NOt of metaprolol tartrate using different grades and 
levels of hydroxypropyl Methylcellulose(Methocel K4M, K15M, 
k100M, and K100V). Different granulation techniques were 
evaluated such as direct compression; fluid-bed and high shear 
granulation. Direct compression formulations exhibited poor flow, 
picking, and, sticking problems .High-shear granulations resulted 
in the formation of hard granules but yielded good tablets,Fluid-
bed granulations were satisfactory in terms of tablets performance. 
The release from formulations containing Methocel K100V was 
found sensitive for changes in polymer concentrations. Thus the 
results lead to the optimization of MetocelK100V as a rate 
controlling matrix. 
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  N.K jain et al.,(2002)38  Controlled release (CR) tablets of 
Diclofenac were developed employing hydroxypropyl 
methylcellulose 1000 (HPMC-1000) and hydroxypropyl 
methylcellulose 15000 (K-15 Methocel) as matrices. A priming 
dose of diclofenac was contained in the first layer and the 
maintenance dose was in the second layer in the HPMC-1000 or 
K-15 Methocel matrix to obtain release rates of the drug of 
approximately 8 mg h
−1
 for an extended period of time. The 
comparative in vivo evaluation of the K-15 Methocel tablet and 
Voltarol
®
 50 (diclofenac 50 mg enteric tablet) in human volunteers 
showed that, the matrix tablet, a quicker onset of action and a more 
uniform plasma level of diclofenac around the maximum 
concentration could be maintained as compared to Voltarol
®
 50.  
  Eddy Castellanos Gil et al., (2006)39 developed controlled 
delivery system for propranolol hydrochloride (PPL). The 
influence of matrix forming agents (native dextran, hydroxypropyl 
methylcellulose (HPMC), cetyl alcohol) and binary mixtures of 
them on PPL release in vitro was investigated. The sustained-
release matrix tablets with good physical, mechanical and 
technological properties were obtained with a matrix excipient:PPL 
ratio of 60:40 (w/w), with a dextran:HPMC ratio of 4:1 (w/w) and 
with a cetyl alcohol amount of 15% (w/w). The in vitro dissolution 
profiles of sustained-release matrix tablets of racemic PPL were 
determined and compared with the United States Pharmacopeia 
(USP) tolerance specifications for Propranolol Hydrochloride 
Extended-Release Capsules A comparative kinetic study of the 
present matrix tablets was established. The value for the similarity 
factor (f2 = 69.6) concluding that the dissolution profile of the 
present two sustained-release oral dosage forms are similar, and 
the codependent mechanism of drug release was established. 
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  Angel Concheiro et al.,(1999)40  assessed  the  potential  value of 
(HPMC) mixtures as gelling agents in matrix tablets for 
hydrosoluble drugs. Experiments were carried out with 
Methocel
R
 K100LV (an HPMC with nominal viscosity of 100 cP) 
and Methocel
R
 K100M (an HPMC with nominal viscosity of 
100000 cP). Rheological characterization of 2% dispersions of the 
polymers, and of 30:70, 50:50 and 70:30 mixtures, indicated that it 
is possible to obtain a wide range of rheological behaviours by 
mixing K100LV and K100M, were obtained and that the two 
polymers display rheological antagonism. Trials were carried out 
with atenolol tablets made with 40% or 80% gelling agent (i.e. 
K100LV, K100M or one of the K100LV:K100M mixtures). 
Analysis of drug dissolution profiles in 0.1 N HCI, on the basis of 
Higuchi's model and the equation of Korsmeyer and coworkers, 
indicated that drug release in all cases was diffusion-limited.  
  Rajesh Kaza, et al.,(2010)41  optmized the formulation for the 
delayed and extended release tablets of mesalamine,  by wet 
granulation technique using the polymers, such as HPMCK-100M, 
HPMC K4M, HPMCE15 and HPMC E5. It was found that the best 
formulation showed 98.75 % of drug release at the end of 10 th 
hour. In-vitro drug release studies of mesalamine delayed and 
extended release tablets showed that, the rate of the drug release 
follows first order kinetics as indicated straight line with good 
correlation coefficient for the plot of log percentage drug 
remaining vs time. The rate of drug release was found to be 
dissolution control as there was a good correlation coefficient for 
the plot of Hixon-Crowell cube–root law. 
  Shinichiro Tajiri et al.,(2010)42 developed an extended release 
dosage form of Cevimeline. Two types of extended release 
tablets(simple matrix table and press-coated tablets) and their 
potential as extended release dosage forms were assessed. Simple 
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matrix table have a large amount of hydroxypropylcellulose as a 
rate controlling polymer and the matrix is homogenous throughout 
the tablet. The press-coated consista of a matrix core, which was 
completely surrounded by an outer shell containing large amount 
of hydroxypropylcellulose .The simple matrix tablets could not 
sustain the release of Cevimeline effectively. In contrast, the press-
coated tablets shoed a slouer dissolution rate compared with the 
simple matrix tablets and the release curve was nearly linear. The 
dissolution of Cevimeline from the press-coated tabltes was not 
markedly   affected by the pH of the dissolution medium. 
  Syed Namath Ulla,  et al.,(2009) 43   developed   Lornoxicam SR 
matrix tablets that provide complete drug release that starts in the 
stomach to rapidly alleviate the painful symptoms and continues in 
the intestine to maintain analgesic effect. Drug-polymer 
compatibility studies by FTIR gave confirmation about heir purity 
and showed no interaction between drug and selected polymers. 
Various formulations were developed by using release rate 
controlling and gel forming polymers like HPMC (K4M, K15M, 
K100M) by direct compression method. It was concluded that the 
release followed zero order kinetics, as the correlation coefficient 
(R2 value) was higher for zero order release, so the drug release 
mechanism is controlled release. The best formulation was found 
to be stable during stability studies for two months. Thus, best 
formulation satisfied physic-chemical parameters and in vitro drug 
release profile requirements for a sustained drug delivery system. 
  Amelia Avachat et al.,(2007)44  developed and characterized an 
oral controlled release drug delivery system for concomitant 
administration of Diclofenac sodium(DS) and chondroitin 
sulfate(CS). A hydrophilic matrix-based tablet using different 
concentrations of HPMC was formulated. The in vitro drug release 
study revealed that HPMC K 100CR at concentration of 40% of 
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the weight of the dosage form was able to control the release of 
both DS and CS for 9 hours. The release of DS matched with the 
marketed CR tablet of DS. The in vitro release data of CS and DS 
followed Korsmeyer-Peppas and zero order kinetics respectively. 
  Jaleh Varshosaz et al.,(2006)45 formulated sustained release 
tablets of highly water-soluble Tramadol HCL. Matrix tablets of 
Tramadol were produced by direct compression method. Different 
concentrations of polymers and the combination of polymers 
(HPMC, Xanthum gum, Guar gum) were applied. After evaluation 
of physical parameters, the dissolution test was performed in the 
phosphate buffer media (pH 7.4) up to 8 hours. Tablets with only 
Xanthum gum had the highest mean dissolution time; the least 
dissolution efficiency .The release followed zero order models via 
swelling, diffusion, and erosion mechanism. Guar gum alone could 
not efficiently control the release while Xanthum gum and all 
combinations of natural gums with HPMC could retard Tramadol 
HCL release. 
  Zeng W.M et al.,(2004)47 developed  an oral sustained release 
matrix formulation of a highly water-soluble drug (Ranitidine 
HCL). It was designed and developed to achive a 24 hour release 
profile. Sodium alginate formulaton matrices containing Xanthum 
gum or zinc acetate or both were investigated. The results showed 
that the presence of both Xanthum gum and zinc acetate in sodium 
alginate matrix played a key role in controlling the drug release for 
24 hours. Evaluation of the release data showed the release 
mechanism for the novel formulation might be attributed to the 
diffusion of the drug. 
  SC Basak et al.,(2004)47 Propranalol Hydrochloride matrix tablets 
were prepared with HPMC polymer to control the release of drug 
with a view to develop sustained release dosage form. The 
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resulting matrix tablets were prepared with HPMC K4M fulfilled 
all the official requirements of tablet dosage forms. The in vitro 
drug release was measured for a total period of 12 hours using 
1.2pH buffers for first 1 hour and pH 7.5 buffers for the rest of the 
period. The drug release was within the limits (USP requirements). 
The results provide a method of achieving sustained drug action 
through uniform drug release. 
  Shao Z.J et al., (2001)48 studied the release of Diphenhydramine 
HCL matrix tablets composed of PVP and povidone(Kollidon SR). 
kollidon SR was found to provide a sustained release effect for the 
model compound, with certain formulation and processing 
variables playing an important role in controlling its release 
kinetics. Stability studies conducted at 40˚C/75% RH revealed a 
slowdown in dissolution rate for the drug –kollidon SR 
formulation, as a result of polyvinyl acetate relaxation. The release 
mechanism of kollidon formulation appears to be diffusion 
controlled,while that of drug-Kollidon-lactose formulation appears 
to be controlled predominantly by diffusion along with erosion. 
  James L. Ford et al., (1999)49  evaluated the relationship and 
influence of formulation and technological factors such as Drug: 
HPMC ratio, particle size of the drug, particle size of HPMC and 
compression force, on drug release from matrices containing 
HPMC and Diclofenac sodium as a model drug. The influence of 
these variables was assessed by multi-way analysis of variance. 
The results of the study point out   the rate and mechanism of  
Diclofenac sodium release from HPMC K15 M matrices are 
mainly controlled by the Drug: HPMC ratio. The drug and HPMC 
particle size also influence the drug release parameters, although to 
a lesser extent. Finally,the independence of the drug release from 
the matrix tablets with respect to the compression force is reported. 
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  Subal C.basak et al.,(2010)50  enteric coated Aceclofenac matrix 
tablets were formulated as sustained release tablets employing 
HPMC. Tablets using different drug polymer ratios of HPMC were 
prepared by wet granulation technique. Formulation was optimized 
on the basis of acceptable tablet properties and in vitro drug 
release. Aceclofenac release from tablets was extended from 16 to 
24 h from formulated batches.the release kinetics was found to be 
followed Higuchi model.the tablets shown diffusion dominated 
drug release. 
  Praveen S. Hiremath et al.,(2008)51  developed a controlled 
release (CR) matrix tablet formulations of Rifampicin and 
Isoniazid combination, a series of formulations were developed 
with different hydrophilic polymers hydroxypropyl 
methylcellulose (HPMC) and hydroxypropyl cellulose (HPC) in 
varying polymer ratios and procressing techniques. Further, 
Eudragit L100-55 was incorporated in the matrix tablets to 
compensate for the pH-dependent release of rifampicin. 
Rifampicin was found to follow linear release profile with time 
from HPMC formulations, and with HPC, there was an initial 
higher release in simulated gastric fluid (SGF) followed by zero 
order release profiles in simulated intestinal fluid (SIFsp) for 
Rifampicin. The release of Isoniazid was found to be 
predominantly by diffusion mechanism in HPMC formulations, 
and with HPC formulations release was due to combination of 
diffusion and erosion. From this it was concluded that the initial 
release was sufficiently higher for rifampicin from HPC thus ruling 
out the need to incorporate a separate loading dose.  
  James L. Ford et al.,(2002)52  formulated a sustained release 
promethazine hydrochloride tablets using hydroxypropyl-
methylcellulose matrices .The ratio of  promethazine: HPMC was 
the major rate controlling factor. A straight-line relationship 
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existed between the Higuchi-type release rate and the reciprocal of 
the tablet content of HPMC. The study was continued increasing 
the particle size range of promethazine from 45–63 to 500–700 μm 
which produced only a 12% increase in the drug release rate. 
Increase in the compaction pressure does not modify the release. 
The study concluded that the lowest viscosity grade of HPMC used 
(HPMC K100) gave the highest release rates at constant HPMC: 
drug ratio. The other three grades (HPMC K4M, K15M and 
K100M) also showed similar release rates despite the variation in 
their molecular size. 
  Efentakis Manuel et al., (1990)53  modeled the drug release from 
hydrophobic matrices by use of thermodynamic activation 
parameters. Sustained release tablets of indomethacin were 
prepared using Eudragit RS. Two types of formulation were 
considered, one was a directly compressed powder mixture which 
produced a matrix system, and the other was prepared by 
granulation, such that the drug was to some extent sealed within a 
cast film of the polymer. Dissolution studies (USP paddle) 
revealed that the drug release from the matrix was directly 
proportional to the concentration of the polymer that was used. 
Drug release from the granulated system was much slower than 
from the directly compressed matrix. 
  Sung-Hyun Park et al., (2005)54 studied the Preparation of an 
extended-release matrix tablet using chitosan/Carbopol 
interpolymer complex. A chitosan and Carbopol interpolymer 
complex (IPC) was formed using a precipitation method in an 
acidic solution. The chitosan and Carbopol IPC was characterized 
by Fourier transform infrared spectroscopy (FT-IR), differential 
scanning calorimetry (DSC), and turbidity measurements. FT-IR 
demonstrated that the IPC formed a complex through an 
electrostatic interaction between the protonated amine (NH3
+
) 
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group of chitosan and the carboxylate (COO
−
) group of Carbopol. 
DSC indicated the IPC to have different thermal characteristics 
from chitosan or Carbopol. The turbidity measurement revealed the 
complexation ratio of IPC between chitosan/Carbopol to be 1/4. A 
theophylline tablet was prepared using the IPC as a matrix 
material. The drug release profile from this tablet was similar to 
that from the HPMC tablet and showed a pH-independent release 
profile. The mechanisms for drug release from the IPC tablet were 
diffusional release at pH 6.8 and relaxation release at pH 1.2. 
  J. L. Pedraz et al.,(2002)55  studied the release of ketoprofen 
enantiomers from HPMC K100M matrices. They studied the 
sustained release formulation of ketoprofen elaborated with HPMC 
K100M on the hypothesis that chiral excipient can 
stereoselectively affect the release of the racemic drug. They 
observed the differences in the percentage release between 
enantiomers show the existence of chiral interaction between 
ketofrofen and HPMC K100M. 
  Dhake A.S et al..(2005)56 studied the formulation and release 
characteristics of sustained r elease ofloxacin tablets using HPMC 
in various ratios. They concluded that HPMC cellulose is an 
appropriate polymer that can be utilized as matrix forming agent to 
prolong the release of drug 
  Yihong Qiu et al.,(1997)57 formulate sustained release hydrophilic 
matrix of zileuton and perform in vitro and in vivo studies. They 
studied the prototype formulation with drug loading of 50 to 60 % 
were prepared and tested for in vitro using USP appratus I, II  and 
III  in absorption of three formulation with different release rate 
were evaluated in beagle dog. In vivo drug release data were 
corelated with in vitro release and they observed linear 
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relationships between in vitro and in vivo release with more rapid 
in vivo release than in vitro. 
  B. Parthsarthi G et al., (2011)58 Formulated Omeprazole delayed 
release tablets. The omeprazole magnesium compressed tablets 
were optimized for all physical parameters and the,optimized . 
Eudragit L30D55was selected as enteric coating polymer, and the 
tablet   having tbest dissolution profile for a delayed period of time 
which shown 102.43% at end of12th hour. The release profile of 
omeprazole magnesium from enteric coated tablets has shown a 
slow release following first order kinetic with non- Fickian 
mechanism. . 
  Anroop B Nair1 et al.,(2010)59   formulated and evaluated enteric 
coated tablets for esomeprazole magnesium trihydrate. Different 
core tablets were prepared and a formulation was selected for 
further enteric coating, based on the disintegration time.. Enteric 
coating was carried out using different polymers like Eudragit L-30 
D-55, hydroxy propyl methylcellulose phthalate, cellulose acetate 
phthalate and Acryl-EZE® to achieve 5% weight gain, coating was 
optimized to 8% w/w. In vitro analysis of the developed tablets 
was carried out. This study concluded that enteric coated tablets of 
esomeprazole can be prepared using any of the enteric coating 
polymer studied using a minimal weight gain of 8%.  
 
 
 
 
 
  
 
Chapter 3 
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Aim of the present investigation 
 The present investigation relates to the development of extended release 
matrix tablets containing Oxybutynin Hydrochloride for the treatment of over 
reactive urinary bladder. Oxybutynin Hydrochloride is an anticholinergic agent, 
having short half life of (2-3hours) the development of extended release 
formulations of Oxybutynin Hydrochloride is therefore therapeutic relevance and 
can be used to provide a consistent dosage through extending an appropriate level of 
drug over time. 
           To achieve this goal various prototype formulation trials are taken and 
evaluated with respect to the various quality control such as dissolution. The formula 
will be finalized by comparing the in vitro dissolution profile with that of the 
Ditropan tablets. 
Reason for selection of delayed release dosage form: 
 Due to instability in acidic environment, a trail was made to by-pass the 
stomach by using enteric coating which thereby improves bioavailability and 
therapeutic efficacy with no degradation of drug.  
Objective of the study 
               The overall objective was  
 To formulate and evaluate Extended release tablets of Oxybutynin 
Hydrochloride. 
 To determine the best fit dissolution profile for dosage form.  
 To study the release profile of the dosage form and to compare 
their drug-release profiles with the Ditropan(innovator). 
 To study the stability of the optimized formulation 
 
  
 
Chapter 4 
Drug and Excepients Profile 
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Drug Profile 
Oxybutynin Hydrochloride:
 60- 64
 
                Oxybutynin Hydrochloride is an anticholinergic and antispasmodic 
medication used to relieve urinary and bladder difficulties, including frequent 
urination and inability to control urination, by decreasing muscle spasms of the 
bladder. It competitively antagonizes the M1, M2, and M3 subtypes of the 
muscarinic acetylcholine receptor. 
Structure: 
 
Chemical name             :  4-(diethylamino)but-2-yn-1-yl2-cyclohexyl-2- 
hydroxy-2-phenylacetate hydrochloride.                                                         
Description                    :  Oxybutynin chloride ia a white or almost white to   
crystalline Oxybutynin chloride is a racemate of R- 
and S- enantiomers. 
Molecular formula         :  C22H31NO3.HCL 
Melting point                   :  124 °C to 129 °C. 
Molecular weight            :  394.0 
Solubility                         :  Freely soluble in water and ethanol (96%), Soluble in 
acetone, slightlysoluble in ether Insoluble in 
cyclohexane.   
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BCS Class                       :  Class 1 
Functional category        :  Antispasmodic In the treatment of over reactive 
Urinary bladder. 
Storage conditions        :  Store in air tight containers, Protect from light. 
Pharmaco kinetic parameters:
 65, 66
 
Absorption: 
              Following the first dose of oxybutynin chloride extended release tablets, 
oxybutynin plasma concentrations rise for 4 to 6 hours; and from there steady 
concentrations are maintained for up to 24 hours.  
Distribution: 
             The apparent volume of distribution is approximately 193 L. The serum 
protein binding of oxybutynin chloride was about 83-85%, primarily to albumin. 
Metabolism:  
 Oxybutynin Hydrochloride is metabolized primarily by the cytochrome 
P450 enzyme systems, Particularly CYP3A4 found mostly in the liver and gut wall. 
Its metabolic products include phenylcyclohexylglycolic acid, which is 
pharmacologically inactive, and desethyloxybutynin, which is pharmacologically 
active. Following oxybutynin chloride extended release tablet administration, 
plasma concentrations of R- and S-desethyloxybutynin are 73% and 92%, 
respectively, of concentrations observed with oxybutynin. 
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Elimination:  
 Oxybutynin is extensively metabolized by the liver, with less than 0.1% 
of the administered dose excreted unchanged in the urine. Also, less than 0.1% of 
the administered dose is excreted as the metabolite desethyloxybutynin. 
Mechanism of action: 
 Oxybutynin Hydrochloride is an anticholinergic agent, it exerts 
antispasmodic effect on smooth muscle and inhibits the action of acetylcholine at 
post ganglionic cholinergic sites, thus increasing bladder capacity and delaying the 
initial desire to void by reducing the number of motor impulses reaching the detrusor 
muscle. oxybitynin Hydrochloride does not block acetylcholine effect at skeletal 
myoneural junctions or at autonomic ganglia; neither does it have effect on the 
smooth muscle of blood vessels.  
Therapeutic Uses:  
 Urge incontinence, over reactive urinary bladder, nocturnal enuresis. 
Dosage:     
 5mg three times daily to obtain clinical response, in case of nocturnal 
enuresis a single dose of 5-10mg before bed time can be administered. 
Over Dose:    
 Drowsiness, hallucinations, dilation of pupils,urinary retention. 
Storage: 
  Store between 15
0
c to 30
0
c. 
Contraindications: 
 Myasthenia gravis. 
 Narrow-angle glaucoma or shallow anterior chamber. 
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 Gastrointestinal obstruction including paralytic ileus, intestinal 
atony. 
 Patients with bladder outflow obstruction where urinary retention 
may be precipitated. 
Adverse effects 
        Dry mouth, difficulty in urination, constipation, blurred vision, 
drowsiness and dizziness. Anticholinergics have also been known to induce 
delirium. 
Use in Specific Populations: 
Nursing Mothers: 
        Oxybutynin chloride and its metabolites are excreted in the breast milk of 
animals. Oxybutynin chloride   excretion in human milk has been detected in a study 
of a single nursing mother after a single 10 mg oral dose. Approximately 60%, of 
that found in maternal blood. Therefore breast-feeding mothers should avoid taking 
oxybutynin. 
Pediatric Use: 
        Oxybutynin chloride is safer in children over five years of age, and may 
be given in doses up to 5mg twice daily for enruesis without any serious adverse 
effects. Some facial flushing is experienced by 80%of children when the drug is 
initially prescribed but this usually subsides after the first month of therapy. 
Gender:   
 There is a modest rise in Oxybutynin chloride AUC and Cmax in women 
than men.                                                 
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Excipients Profile  
Hydroxypropyl MethylCellulose
65
 
Synonyms: Hydroxypropylmethylcellulose; HPMC; Methocel; Benecel MHPC; 
methyl hydroxy propyl cellulose; methylcellulose propylene glycol ether; Metolose. 
Chemical Name and CAS Registry Number:  
 Cellulose hydroxy propyl methyl ether [9004-65-3] 
Structural formula:  
 
Figure: 7 Structure of HPMC 
Functional category: 
 Coating agent, film-former, rate-controlling polymer for sustained release, 
stabilizing agent, suspending agent, tablet binder, viscosity-increasing agent. 
Physicochemical Properties: 
Description                 :  White to off white powder, free flowing powder 
Particle size                    :  Minimum 95% through a #40 US standard sieve 
Methoxyl content             :  19-24% 
Hydroxypropyl content  :  7-12% 
Bulk density                    :  0.12 – 0.15 g/ml 
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pH (1% content)           :  5.5-8 
Solubility                         :  HPMC K100M is a high viscosity polymer which is 
   soluble in water. 
Table:3 Typical viscosity values for 2% (w/v) aqueous solutions of Methocel 
(Dow chemical Co.). Viscosity measured at 20
0
C 
Methocel product USP 28 designation Nominal viscosity(mPa s) 
Methocel  K4 Premium 2208 4000 
Methocel  K15 Premium 2208 15000 
Methocel  K100MPremium 2208 100000 
Methocel  E4M Premium 2910 4000 
Methocel  F50Premium 2906 50 
Methocel  E10MPremium 2906 10000 
Methocel  E5 Premium 2906 5 
Methocel  E15 Premium 2906 15 
Methocel  K4 E50Premium 2906 50 
Methocel  60SH 2910 50, 4000, 10000 
Methocel  90SH 2208 100, 400, 4000, 1500 
 
Stability and storage:  
      Hypromellose powder is stable material, although it is hygroscopic after 
drying. Solutions are stable at PH 3-11. Increasing temperature reduces the viscosity 
of solutions. Hypromellose undergoes a reversible sol-gel transformation upon 
heating and cooling. The gel point is 50-90
0
C, depending upon the grade and 
concentration of material. 
 Aqueous solutions are comparatively enzyme-resistant, providing good 
viscosity stability during long term storage. However, aqueous solutions are liable to 
microbial spoilage and should be preserved with an antimicrobial preservative. 
Aqueous solutions may also be sterilized by autoclaving; the coagulated polymer 
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must be redispersed on cooling by shaking. Hypromellose powder should be stored 
in a well closed container, in a cool, dry place. 
Applications: 
              Hypromellose is primarily used as a tablet binder, in film coating, and as a 
matrix for use in extended-release tablet formulations. Concentrations between 2% 
and 5% w/w may be used as a binder in either wet- or dry-granulation process. 
High-viscosity grades may be used to retard the release of drugs from a matrix at 
levels of 10-80% w/w in tablets and capsules. Hypromellose is also used as 
suspending agent in topical formulations. Compared with methyl cellulose, 
hypromellose produces aqueous solutions of greater clarity, with fewer undispersed 
fiber present, and is therefore preferred in formulations for ophthalmic use. 
Hypromellose at concentrations between 0.45-1.0% w/w may be added as 
thickening agent to vehicles for eye drops and artificial tear solutions. 
          Hypromellose is also used as an emulsifier, suspending agent, and 
stabilizing agent in topical gels and ointments.  
 In addition, hypromellose is used in the manufacture of capsules, as an 
adhesive in plastic bandages, and as a wetting agent for hard contact lenses. It is also 
widely used in cosmetics and food products. 
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Table:4    Crospovidone
66
 
Synonyms Crospovidonum, Kollidon, Plasdone polyvidone  
polyvinylpyrrolidone, polyvinylpyrrolidone–vinyl acetate 
copolymer. 
Molecular 
weight 
2500–3 000000 
Chemical name 1-Ethenyl-2-pyrrolidinone homopolymer. 
Description Povidone occurs as a fine, white to creamy-white colored, 
odorless or almost odorless, hygroscopic powder. 
Functional 
categories 
Disintegrant, dissolution aid, suspending agent, Tablet binder 
in wet granulation. 
Solubility Freely soluble in acids, chloroform, ethanol (95%), ketones, 
methanol, and water; practically insoluble in ether, hydro -
carbons, and mineral oil. In water, the concentration of a 
solution is limited only by the viscosity of the resulting 
solution. 
Stability,and 
storage 
conditions 
Powder is hygroscopic; it should be stored in an airtight 
container in a cool, dry place. 
Applications Carrier for drugs, Dispersing agent, Suspending agent Tablet 
binder, Tablet diluents or coating agent 
Incompatibility The efficacy of some preservatives, e.g. thimerosal, may be 
adversely affected by the formation of complexes. 
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Table: 5    Microcrystalline Cellulose
67 
 
Synonym Avicel ; cellulose gel; Celphere;  Ceolus KG; 
crystallinecellulose; Emco cel; Ethispheres; Fibrocel; 
Pharmacel. 
Molecular 
weight 
36 000 
Description Microcrystalline cellulose occurs as white, odourless, tasteless, 
Crystalline powder composed of porous particles,ti is 
commercially available in different particle sizes and moisture 
grades. 
Functional 
categories 
Adsorbent agent, suspending agent, Tablet and capsule 
diluents, Tablet disintegrant. 
Solubility Slightly soluble in 5%w/v sodium hydroxide solution, 
practically insoluble in water, dilute acids and most organic 
solvents. 
Stability and 
storage 
conditions 
Microcrystalline cellulose is a stable though hygroscopic 
material. Should be stored in a well-closed container in a cool, 
dry place. 
                           
Applications 
 
 
 
Use Concentration (%) 
Tablet binder/diluents 20-90% 
Tablet sealer  
Incompatibility Incompatible with strong oxidizing agents. 
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Table: 6 Lactose Monohydrate
68
 
Synonyms Pharmatose, DCL, Lactochem, Tablettose, Granulac, 
SpheroLac, Capsulac, Sachelac. 
Chemical Name 
O-b-D-galactopyranosyl-(1!4)-b-D-glucopyranose 
Empirical 
Formula 
C12H22O11 
Molecular 
weight 
360.31 
Description White to off white crystalline particles or powder.it is odour 
less and slightly sweet as sucrose. 
Functional 
categories 
Binding agent, diluents for dry-powder inhalers, Tablet 
binder, Tablet and capsule diluents. 
Solubility practically insoluble in chloroform, ethanol , Soluble in 
water 
Stability and 
storage 
conditions 
Lactose may develop a brown colouration on storage. 
Lactose should be stored in a well-closed container, 
protected from light, in a cool, dry place. 
Applications Anhydrous lactose is widely used in direct compression and 
as a Tablet and capsule filler and binder. Anhydrous lactose 
is used for moisture-sensitive drugs due to its low moisture 
content.Monohydrate; Lactose, Spray-Dried.lyophilization 
aid. 
Incompatibility Lactose is also incompatible with amino acids, 
aminophylline,Amphetamines, and lisinopril. 
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Table: 7 Lubritab
69
 
Synonyms Hydrogenated cotton seed oil(Stereotex),hydrogenated palm 
oil(softisan), Hydrogenated soyabean oil(lipovol). 
Molecular 
weight 
38 000 
Description 
white to yellowish-white with the powder gradesappearing 
more white coloured than the coarser grade.Hydrogenated 
vegetable  oil type 1 occurs as fine powder, flakes or pellets, 
Structural 
formula 
R1COOCH2—CH(OOCR2)—CH2OOCR3 
Functional 
categories 
Tablet and capsule lubricant; Tablet binder. 
Solubility soluble in chloroform, petroleum spirit, and hot 
propan-2-ol; practically insoluble in water. 
Stability and 
storage 
conditions 
Hydrogenated vegetable oil type I is a stable material; 
typically it is assigned a 2-year shelf-life. The bulk material 
should be stored in a well-closed container in a cool, dry 
place. 
Applications It is also used as the matrix forming material in lipophilic-
based controlled release formulations.it is used as tablet 
lubricant in 1-6% concentration. 
Incompatibiliy Incompatible with strong oxidizing agents. 
                                            
 
      
 
 52 
 
 
 
Table: 8 EUDRAGIT L30 D55
70 
Synonyms                    Methacrylic acid copolymer, Eastacryl, Eudragit, Ploy 
Methacrylates,  Kollicoat. 
Chemical name  Poly(methacrylic acid, ethyl acrylate) 1 : 1 
Molecular 
weight 
250,000. 
Description Milky-white liquid of low viscosity with a faint characteristic 
odor. 
Functional 
categories 
Channeling Agent, Enteric coating polymer. 
Solubility The dispersion is miscible with water in any proportion, the 
milky-white appearance being retained. 
A clear or slightly cloudy, viscous solution is obtained by 
mixing 1 part EUDRAGIT® L 30 D-55 with 5 parts acetone, 
and also in isopropyl alcohol. 
Stability and 
storage 
conditions 
Store at controlled room temperatures (USP, General 
Notices). Protect against moisture. Any storage between 8 ° 
and 25 °C fulfils this requirement 
Applications It is used as channeling agent. And it is also used as Enteric 
coating polymer.  
Incompatibility Incompatibilities occur with some polymethacrylate 
dispersions depending upon the ionic and physical properties 
of the polymer and solvent electrolytes, pH changes, some 
organic solvents, and extremes of temperature  
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Table: 9 Tri Ethyl Citrate
71 
Synonyms Citric acid, ethyl ester,Citroflex, Citrofol, Hydagen, 
TEC. 
Chemical Name 2-Hydroxy-1,2,3-propanetricarboxylic acid, triethyl 
ester 
Empirical Formula C12H20O7 
Molecular weight 276.29 
Description Triethyl citrate is a clear, odorless, practically colorless, 
oily liquid 
Functional categories Plasticizer, solvent. 
Solubility Soluble 1 in 125 of peanut oil, 1 in 15 of water. 
Miscible with ethanol (95%), acetone, and propan-2-ol. 
Stability and storage 
conditions 
Triethyl citrate should be stored in a closed container in 
a cool, dry location. 
Applications Triethyl citrate and the related esters acetyltriethyl 
citrate, tributyl citrate, and acetyltributyl are used to 
plasticize polymers in formulated pharmaceutical 
coatings, Triethyl citrate is also used as a direct food 
additive for flavoring, for solvency, and as a surface 
active agent 
Incompatibility Triethyl citrate is incompatible with strong alkalis, and 
oxidizing agents. 
                  
  
 
Chapter 5 
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Plan of Work 
The proposed research work is planned as follows 
 API characterization  
 Preformulation studies   
 Angle of repose, 
 Bulk density, 
 Tap density,  
 Compressibility index, 
 Hausner‘s Ratio, 
 Compatibility studies, 
 Sieve Analysis, 
      
     Formulation and development of Extended release tablet 
     Evaluation of tablets. 
 
 Physical parameters like diameter, thickness, hardness, friability,  
 Determination of drug content 
 In-vitro drug release studies 
 Determination of release kinetics.  
 Selection of formulation on the basis of in-vitro tools. 
 Comparison of formulations with Ditropan & selection of best 
batch. 
 Stability study by ICH guidelines. 
  
 
 
Chapter 6 
Materials and Methods   
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Table: 10 List of Materials used in the study 
S.No Ingredients Manufacturer Supplier 
1. 
Oxtbutynin 
Hydrochloride 
 
Aurobindo Pharma Ltd 
India 
Aurobindo Pharma Ltd 
2. Methocel K100M 
The Dow chemical 
company USA 
The Dow chemical 
company USA 
3. Kollidon 90F 
M/S  Isp Technology 
USA 
Anshul Agencies, 
Mumbai. 
4. 
Microcrystalline 
Cellulose pH102 
Ferro Corporations, USA 
Signet Chemical 
Corporation, Mumbai 
5. Pharmatoe 200 Ferro Corporations, USA SD Fine Chemicals ltd 
6. Lubritab 
DMV Fonterra Excipients 
USA 
Kamarlal & Co, 
Hyderabad 
7. 
Magnesium 
Stearate 
M/S Luzenac Varchisone, 
Italy 
Signet Chemical 
Corporation, Mumbai 
8. Isopropyl alcohol 
M/S  Isp Technology 
USA 
Anshul Agencies, 
Mumbai. 
9. Eudragit L30 D55 Ferro Corporations, USA 
Shree Narsimha Chem. 
Pharma Pvt. Ltd., 
Maharashtra 
10. Opadry 
DMV Fonterra Excipients 
USA 
SD Fine Chemicals ltd 
11. Triethyl citrate 
DMV Fonterra Excipients 
USA 
SD Fine Chemicals ltd 
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Table: 11 List of Equipments used in the study 
 
S. No. EQUIPMENT MANUFACTURER 
1 Granson Vibratory Sifter Granson, Mumbai[Aux 220] 
2 Rapid Mixer Granulator Scucal, Ahmedabad [RMG 4828L] 
3 Tab density Tester Electro lab,Mumbai [ETD 1020] 
4 Homogenizer Remi, Thane [R 012] 
5 Double Cone blender Vamp,Thane [Double cone] 
6 Laboratory Stirrer PMDC Geared [RDT 124A] 
7 Automatic Coating System Neomachines, Kolkata [NEOCOTA -5T] 
8 Rapid dryer Retsch, Hyderabad [TG-200] 
9 pH Meter Thermo ,Mumbai [ORION 2STAR] 
10 
Dissolution test apparatus 
USP Type II 
Lab India [101] 
11 Stability chambers Thermo,Mumbai 
12 Hardness tester BenchSaven [TM-Series] 
13 Roche Friabilator Electro lab,Mumbai [EF-TW] 
14 
Tablet Compression 
machine-16 Station 
Cadmech Machinery co. Pvt.Ltd, 
Ahmedabad[CMD3-16] 
15 Sieve Shaker Retsch, Hyderabad [FR-019] 
16 Weighing Balance Essae, Bangalore [DS-852] 
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6.1    EXPERIMENTAL  
Preformulation Study: 
 Preformulation study can divided into two subclasses 
1. API characterization,  
2. Compatibility study 
6.1.1 Active pharmaceutical ingredient (API) characterization: 
 These are preliminary characteristics of any substance which is useful in 
identification of specific material. Following physical properties of API were 
studied.  
Organoleptic Evaluation    : Oxybutynin Hydrochlorideis a white to off-white 
                                                Crystalline powder. 
Solubility Analysis             :  Freely soluble in water and ethanol (96%) 
Melting Point                     :  124 ºc – 129 ºc 
Loss on drying: 
 1.0 g of sample of Oxybutynin chloride was accurately weighed and the 
powder was kept in a moisture balance apparatus for 5 min, at 105ºCand the 
moisture content was calculated. 
6.1.2 Angle of repose:
 72 
 The frictional force in a loose powder can be measured by the angle of 
repose (θ). It is defined as, the maximum angle possible between the surface of the 
pile of the powder and the horizontal plane. If more powder is added to the pile, it 
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slides down the sides of the pile until the mutual friction of the particles producing a 
surface angle θ, is in equilibrium with the gravitational force.  
 The fixed funnel method was employed to measure the angle of repose. A 
funnel was secured with its tip at a given height (h), above a graph paper that is 
placed on a flat horizontal surface. The blend was carefully pored through the funnel 
until the apex of the conical pile just touches the tip of the funnel. The radius (r) of 
the base of the conical pile was measured. The angle of repose (θ) was calculated 
using the following formula: 
             tan θ = h/r  
Where;     θ = Angle of repose  
               h = Height of the cone  
               r = Radius of the cone base  
Angle of repose less than 30
0
 shows the free flow 
6.1.3 Bulk density: 
 Density is defined as weight per unit volume. Bulk density, ρb, is defined 
as the mass of the powder divided by the bulk volume and is expressed as gm/cm
3
. 
The bulk density of a powder primarily depends on particle size distribution, particle 
shape and the tendency of particles to adhere together.  
               Bulk density is very important in the size of containers needed for 
handling, shipping, and storage of raw material and blend. It is also important in size 
blending equipment.  
 30 g powder blend introduced into a dry 100 mL cylinder, without 
compacting. The powder was carefully leveled without compacting and the unsettled 
apparent volume, Vo, was read. The bulk density was calculated using the formula: 
    ρb = M / Vo 
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           Where,            ρb = Apparent Bulk Density   
                                  M = weight of sample  
                                  V = apparent volume of powder   
6.1.4 Tapped density: 
 After carrying out the procedure as given in the measurement of bulk 
density the cylinder containing the sample was tapped using a suitable mechanical 
tapped density tester that provides a fixed drop of 14 ± 2 mm at a nominal rate of 
300 drops per minute. The cylinder was tapped 500 times initially followed by an 
additional tap of 750 times until difference between succeeding measurement is less 
than 2 % and then tapped volume, Vf was measured, to the nearest graduated unit. 
The tapped density was calculated, in gm per mL, using the formula:  
               ρtap  = M / Vf 
Where, ρtap  = Tapped Density   
                 M = Weight of sample  
                 Vf  = Tapped volume of powder   
6.1.5 Compressibility index: 
 The Compressibility Index (Carr‘s Index) is a measure of the flow 
property of a powder to be compressed. It is determined from the bulk and tapped 
densities. In theory, the less compressible a material the more flowable it is. As 
such, it is measures of the relative importance of interparticulate interactions. In a 
free-flowing powder, such interactions are generally less significant, and the bulk 
and tapped densities will be closer in value. For poorer flowing materials, there are 
frequently greater interparticle interactions, and a greater difference between the 
bulk and tapped densities will be observed. These differences are reflected in the 
Compressibility Index which is calculated using the following formulas: 
 60 
 
 
 Carr’s Index = [(ρtap - ρb) / ρtap] / ×100 
Where,      ρb   = Bulk Density   
                 ρtap = Tapped Density   
Table: 12 Correlation between Carr’s index values and flow properties of 
Powders 
Carr’s index Properties 
5 – 15 Excellent 
12 – 16 Good 
18 – 21 Fair to Passable 
23 – 35 Poor 
33 – 38 Very Poor 
>40 Extremely Poor 
   
6.1.6 Hausner’s ratio:  
 Hausner‘s ratio is the ratio of tapped density to bulk density. Lower the 
value of Hausner‘s ratio better is the flow property.  The powder with Hausner‘s 
ratio less than 1.18, 1.19-1.25, 1.3-1.5 and greater than 1.5 indicates excellent, good, 
passable and very poor flow properties, respectively.  
 Hausner‘s Ratio   = 
DensityBulk
Density  Tapped
 
    Table: 13 Correlation between Hausners ratio values and flow   properties. 
Hausners ratio Properties 
1.0-1.11 Excellent 
1.12-1.18 Good 
1.19-1.25 Fair and aid not needed 
1.35-1.45 Poor must agitate 
> 1.5 Poor 
Above 2 Extremely Poor 
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6.1.7 Drug Excipient Compatibility Studies: 
 The compatibility of drug and formulation components is important 
prerequisite before formulation. It is therefore necessary to confirm that the drug 
does not react with the polymers and excipients under experimental conditions and 
affect the shelf life of product or any other unwanted effects on the formulation. 
Procedure: 
 Drug is mixed with excipients in different ratio. These mixtures were kept 
in a 5ml glass vials and packed properly. These vials are exposed to 40˚ C / 75 % 
RH. Observations for physical appearance are made at initially, 2 week, and 4week, 
the samples were withdrawn for analysis of following parameter: 
1. Appearance and physical conditions 
2. IR Analysis. 
6.1.8 Sieve Analysis: 
 The procedure involves the Electromagnetic Sieve shaking of the sample 
through the series of successively arranged sieves (sieve no. - 25, 30, 40, 60, 80,100 
and pan weight), and weighing of the portion of the sample retained on each sieve 
and calculate percentage retained on each sieve. 
6.2 Formulation Study: 
Formulation Development of Oxybutynin hydrochloride Extended release 
Tablets: 
 Based on preformulation data wet granulation method was selected due to 
poor flow properties and other characteristics from preformulation and different 
formulation trials are tabulated below. The excipients selected based on 
compatibility study and are commonly used excipients. 
 In the trials different binder, Lubricant, concentrations is taken and 
compressed the tablets at different conditions and observer the change 
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6.2.1 Table: 14  Formulation development of Oxybutynin Hydrochloride 
Extended Release tablets 
INGREDIENTS F1 F2 F3 F4 F5 F6 F7 F8 F9 
Oxybutynin 
Chloride 
15 15 15 15 15 15 15 15 15 
MethocelK100M 
CR grade 
80 70 50 55 60 50 45 40 40 
Kollidon 90F -- -- 10 5 -- -- -- -- -- 
Pharmatose 
200 M 
50 65 70 70 70 80 85 90 90 
Avicel PH 102 
45 45 45 45 45 45 45 45 45 
Isopropyl 
Alcohol 
-- -- q.s q.s -- -- -- -- -- 
Purified water -- -- -- -- q.s q.s q.s q.s q.s 
Lubritab 10 8 8 8 6 6 6 6 6 
Magnesium 
stearate 
-- 2 2 2 4 4 4 4 4 
Eudragit 
L30D55 
4.5 4.5 4.5 9 9 9 9 9 9 
Triethyl citrate 0.5 0.5 0.5 0.5 1 1 1 1 1 
Opadry 5.25 5.25 5.25 5.25 5.25 5.25 5.25 5.25 5.25 
 
           
 
 
 
 63 
 
 
     DISPENSING 
             SIFTING 
     MIXING AND GRANULATION 
 
LUBRICATION  
 
SIFTING AND MILLING 
         BLENDING 
DRYING 
 
     COMPRESSION  
 
     ENTRIC COATING 
      
 
CORE TABLET 
 
     FILM COATING 
      
                                      
                                 
 
 
 
 
        
 
 
 
                                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                  
Fig: 8 Flow Chart for Manufacturing Process. 
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6.3   Procedure:   
6.3.1 Sifting: 
 Oxybutynin Hydrochloride, MethocelK100M, pharmatoze200, and 
avicel101 and sifted through #40 mesh are collected separately. 
6.3.2 Dry mixing: 
 Mixing was done in RMG (2.0 Lt Capacity) for 10 min with impeller 
slow speed and chopper off. 
6.3.3 Granulation: 
6.3.3.1 Binder addition: 
 The binding solvent 100g in two proportions of 50g was added for 45sec 
with the impeller slow and followed by the addition of 50g for 45sec with the 
impeller speed and chopper slow. 
6.3.3.2 Granulation: 
 Binder solution added slowly for 90 sec with chopper off and impeller 
fast. Then Rinse the vessel and add for 60 sec. Then kneading carried out for 120 sec 
with chopper slow and impeller fast. 
Table: 15 Considerations in Granulation. 
Condition Time Impeller Speed Chopper 
Dry Mixing 1200 sec 100 rpm 0 
Solvent Addition 40 sec 150 rpm 0 
Mixing time 60 sec 150 rpm 0 
Kneading Time 120 sec 150 rpm 1000 rpm 
Removal 60 sec 100 rpm 0 
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6.3.3.3 Drying: 
1. Wet mass was dried in rapid mixer dryer at 60°C until the loss on 
drying was not more than 2 % w/ w. (Determined by  Moisture 
analyzer at 105°C) 
2. Pooled sample from different locations of rapid mixer Dryer bowl 
were taken and Loss on Drying (LOD) was studied at 105° C on 
Moisture Balance the LOD after drying was - below 2%. 
6.3.3.4 Milling & sifting: 
             Dried granules were sifted through # 60 and the retentions were milled 
through 1.0 mm screen, medium speed with knives forward direction in 
comminuting mill. The milled material was sifted through # 30 mesh. Process 
continued till all the dried granules pass through # 30 mesh. 
6.3.3.5 Blending: 
 The sifted granules of above step were first mixed with the extra granular 
quantity lubritab, magnesium stearate (sifted through # 60 mesh) . The blend was 
mixed in a double cone blender unloaded and compressed into tablets. 
6.3.3.6 Compression: 
 Compression was done using 7.2mm standard concave shaped plain dies. 
Tablet compression parameters: 
Weight of the Tablet             :  200 mg 
Hardness range                 :  12-14 kP 
Thickness ranges               :  3.82 ± 0.3 mm. 
There are various in process control parameters should be performed.  
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6.3.3.7 During tablet compression:      
 Appearance 
                 Weight uniformity  
                  Friability  
6.4 Enteric Coating: 
Procedure for Enteric coating of tablets: 
1.  Enteric coating solution was prepared by slowly dispersing 
EudragitL30D55 in water and homogenize for 30 minutes.  
2.  The dispersion was sifted through muslin cloth and collected into a 
stainless steel vessel.  
3.  The enteric coating dispersion was started spraying with following 
parameters.   
6.4.1 Enteric coating Parameters:- 
 Inlet Temperature              :   45-50
0
C 
 Exhaust Temperature           :   38-42
0
C 
 Atomization                            :   1.2 kg/Cm
2 
 Pan Rotation                          :   8-11 
 Spray rate                             :  2-5gm/min 
 Needle gun pressure             : 0.8 mm. 
   
 The dispersion was kept under continuous stirring, during the coating 
process. The coating was continued till target weight build up was achieved. 
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4.  After target build up was achieved the pan speed was reduced and 
spraying of enteric coating dispersion was stopped and the tablets 
were warmed at the temperature of 38C – 40C for one hour. 
5.  The enteric coated tablets   were collected into a container. 
6.4.2 Description of Enteric coated tablets: 
 White, round shaped, concave tablet and plain on both sides. 
6.4.3 Evaluation of Core and Enteric coated tablets: 
6.4.3.1 Thickness: 
             Twenty tablets from the representative sample were randomly taken and 
individual tablet thickness was measured by using digital vernier calipers. Average 
thickness and standard deviation values were calculated. 
6.4.3.2 Hardness 
 Tablet hardness was measured by using Monsanto hardness tester. From 
each batch six tablets were measured for the hardness and average of six values was 
noted along with standard deviations. 
6.4.3.3 Friability Test:  
 From each batch, 10 tablets were accurately weighed and placed in the 
friability test apparatus (Roche friabilator). Apparatus was operated at 25 rpm for 4 
minutes and tablets were observed while rotating. The tablets were then taken after 
100 rotations, dedusted and reweighed. The friability was calculated as the 
percentage weight loss. 
Note:  No tablet should stick to the walls of the apparatus. If so, brush the walls 
with talcum powder. There should be no capping also. 
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      % Friability was calculated as follows 
 % Friability = (W1 – W2) x 100/W1 
   Where, W1 = Initial weight of the 20 tablets. 
                     W2 = Final weight of the 20 tablets after testing. 
   Friability values below 1 % are generally acceptable. 
6.4.3.4 Weight Variation Test: 
                  To study weight variation individual weights (WI) of 20 tablets from each 
formulation were noted using electronic balance. Their average weight (WA) was 
calculated. Percent weight variation was calculated as follows. Average weights of 
the tablets along with standard deviation values were calculated. 
                    % weight variation = (WA–WI) x 100/ WA 
  As the total tablet weight was 200 mg, according to IP 2010, out of 
twenty tablets ± 10 % variation can be allowed for not more than two tablets. 
  According to USP 2004, ± 10 % weight variation can be allowed for not 
more than two tablets out of twenty tablets. 
6.5 Film Coating: 
6.5.1 Procedure for Film coating of Enteric coated tablets: 
1.  Film coating solution was prepared by slowly dissolving opadry in 
water and homogenize for 45minutes.  
2.  The solution was sifted through muslin cloth and collected into a 
stainless steel vessel.  
3.  The Film coating solution was started spraying with following 
parameters.   
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6.5.2 Film coating Parameters:- 
           Inlet Temperature           :    60˚C 
           Exhaust Temperature     :   42
0
C-45˚C 
          Atomization                       :   1.5kg/Cm
2 
           Pan Rotation                     :   8-10 
          Spray rate                          :   2-5gm/min 
                 Needle gun pressure         :   0.8 mm. 
  The solution was kept under continuous stirring, during the coating 
process. The coating was continued till target weight build up was achieved. 
4.  After target build up was achieved the pan speed was reduced and 
spraying of Film coating solution was stopped and the tablets were 
warmed at the temperature of 38C – 40C for one hour. 
5.  The enteric coated tablets   were collected into a container. 
6.5.3 Description of film coated Tablets: 
 White, round shaped, concave tablet and plain on both sides. 
6.6 Preparation of Standard Curve: 
6.6.1 Standard plot using 6.8 pH phosphate buffer: 
          Accurately weighed quantity (100mg) of  Oxybutynin Hydrochloride was 
taken and dissolved in 10 ml of water in standard flask and  made up to 100 ml with 
phosphate buffer pH 6.8  (1000 ug/ml concentration). From this 1 ml was taken  and 
made up to 100 ml with phosphate buffer pH 6.8, it was used as stock solution . 
From the above stock solution 1ml, 2 ml, 3 ml, 4 ml and 5ml were taken and diluted 
to 10 ml, with phosphate buffer pH 6.8 to produce concentration of 1µg/ml, 2 µg/ml, 
3µg/ml, 4 µg/ml, 5 µg/ml. The absorbance of the resulting solutions was measured 
at 220 nm using UV-spectrophotometer with phosphate buffer pH6.8 as blank. 
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Standard curve was plotted by taking concentration on X-axis and absorbance on Y-
axis.  
6.6.2 Standard plot using 0.1 M HCl: 
 Accurately weighed quantity (100mg) of Oxybutynin Hydrochloride was 
taken and dissolved in 10 ml of water in standard flask and made up to 100 ml with 
0.1M  HCl (1000 µg/ml concentration). From this 1 ml was taken  and made up to 
100 ml with 0.1M HCl , it was used as stock solution . From the above stock 
solution 1 ml, 2 ml, 3 ml, 4 ml, and  5 ml, were taken and  diluted with 0.1M HCl to 
produce concentration  of 1µg/ml, 2µg/ml, 3µg/ml, 4µg/ml and 5µg/ml,. The 
absorbance of the resulting solutions was measured at 220 nm using UV-
spectrophotometer with 0.1 M HCl as blank. Standard curve was plotted by taking 
concentration on x-axis and absorbance on y-axis.  
6.6.3 Evaluation of Oxybutynin Hydrochloride enteric coated Tablets: 
 Acid resistance  
 Assay  
 Dissolution (acid stage followed by buffer stage) 
6.6.4 Procedure for preparation of solutions: 
0.1 M Hydrochloric acid:  
 Dilute 8.5 ml of Hydrochloric acid with purified water to   1000 ml. 
pH 6.8  Phosphate  buffer:  Transfer accurately 250 ml of 0.2M monobasic 
potassium phosphate and 112.0 ml of 0.2M Sodium hydroxide to a suitable  
container and dilute to 1000 ml with purified water.  
pH 6.8 Buffer preparation:   Dissolve 8.77g of Dipotassium hydrogen 
orthophosphate (K2HPO4) in 500 ml of Milli-Q water. Dilute to 1000 mL with Milli-
Q water and adjust the pH of the solution to 6.8 with ortho Phosphoric acid. Filter 
through 0.45 µm pall Pharma lab Nylon 66 membrane filter. 
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6.6.5    Acid Resistance Test: 
   Parameters: 
 Medium  :   0.1 M HCl 
         Volume    :   900 ml 
         Apparatus   :   USP-II, paddle 
         Speed  :   50 rpm 
        Temperature     :   37 ± 0.5
0
C 
Procedure:  
 Place the tablet in the basket; note the initial and final weights of the 
tablet. Physical observations were done on the tablet and write the condition of it.  
6.7  ASSAY  : 
6.7.1 Procedure for Assay of Oxybutynin hydrochloride: 
6.7.1.1 Preparation of standard solution: 
 Weigh a quantity of 10mg  standard oxybutynin Hydrochloride powder 
and transfere into 100ml volumetric flask and dilute it to 100ml with 
methanol.pippet out 1 ml of the above solutiion to 10ml volumetric flask and make 
up the volume with methanol. 
6.7.1.2   Preparation of Sample solution: 
 Weigh a quantity of the tablet powder equivalent to 10mg of oxybutynin 
Hydrochlorideand transfer into 100ml volumetric flask and dilute it to 100ml with 
methanol.pippet out 1 ml of the above solutiion to 10ml volumetric flask and make 
up the volume with methanol. 
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           The absorbance of the above standard  and  sample was measured using 
UV spectroscopy at 220nm. 
6.8    Dissolution Studies: 
 The dissolution was carried out for different experimental trials and also 
for the Ditropan. The various results that are obtained are tabulated below. 
Dissolution studies are carried out in the following medias.          
6.8.1 Acidic Stage:   
Medium         :  0.1M HCl 
 Type of apparatus           :   USP -   II (paddle type) 
 RPM              :   50 
 Volume                      :  900 ml 
 Temperature                    :   37º C ± 0.5 
 Time               :   2 hrs 
6.8.2 Buffer Stage: 
 Medium         :  pH 6.8 Phosphate buffer 
 Type of apparatus            :  USP -   II (paddle type) 
 RPM              :  50 
 Volume                      :  900 ml 
 Temperature             :  37ºC ±  0.5 
 Time               :  24hours 
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6.8.3   in vitro drug release studies
:
  
 in vitro drug release studies were carried out using USP dissolution  
apparatus type II, with 900ml of dissolution medium maintained at 37±0.5°C for 
24hrs, at 50 rpm, pH 6.8 ±0.2 phosphate buffers as dissolution medium. 
           Sample was withdrawn at predetermined time intervals replacing with an 
equal quantity of drug free dissolution fluid. The samples withdrawn were filtered 
through 0.45µ membrane filter, and concentration of drug in each sample was 
analyzed and cumulative percent drug release was calculated. The commercial 
Ditropan XL tablets were used as the reference formulation. 
6.9   Release kinetics
73-75
 
 The results of in vitro release profile obtained for all the formulations 
were plotted in modes of data treatment as follows. 
1. Log cumulative percent drug remaining versus time  
(first order kinetic model)  
 2.  Cumulative percent drug release versus square root of time 
(Higuchi‘s model)  
3.  Cumulative percent drug release versus time  
(zero order kinetic model)        
 4. Log cumulative Percent Drug released versus log time  
(korsmeyers model)  
6.9.1 Drug release kinetics-model fitting of the dissolution Data: 
 Whenever a new solid dosage form is developed or produces, it is 
necessary to ensure that drug dissolution occurs in an appropriate manner. Drug 
dissolution from solid dosage forms has been described by kinetic models in which 
the dissolved amount of drug (Q) is a function of the test time, t or Q = f (t). Some 
 74 
 
 
analytical definitions of the Q (t) function are commonly used such as zero order, 
first order, Higuchi, korsmeyers-peppas models. Other release parameters, such as 
dissolution time (tx%), dissolution efficacy (ED), difference factor (f1), similarity 
factor (f2) can be used to characterize drug dissolution / release profile.  
6.9.1.1 Zero-order kinetics:          
 A zero-order release would be predicted by the following equation.  
               At    =   Ao - Kot             eq ( 1) 
Where, 
 At    =    Drug release at time t 
 Ao   =     Initial drug concentration 
 Ko   =     Zero-order rate constant (hr) 
                 When the data is plotted as cumulative percent drug release versus time if 
the plot is linear then the data obeys zero-order release kinetics, with a slope equal to 
ko. 
Use:  This relation can be used to describe the drug dissolution of several types of 
modified release pharmaceutical dosage forms, as in case of some transdermal 
systems etc. the pharmaceutical dosage forms following this profile release the same 
amount of drug by unit of time and it is the ideal method of drug release in order to 
achieve a prolonged pharmacological action. 
6.9.1.2 First-order kinetics: 
 A first order release would be predicted by the following equation. 
                Log C    =      Log Co -  Kt / 2.303          eq(2) 
Where 
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 C    =   Amount of drug remained at time t 
 Co  =   Initial amount of drug 
 K    =    First-order rate constant 
 When the data is plotted as log cumulative percent drug remaining versus 
time yields a straight line indicating the release follows first-order kinetics, the 
constant k can be obtained by multiplying 2.303 with slope values 
Use:  The pharmaceutical dosage forms containing water-soluble drugs in porous 
matrices, follows this type of dissolution profile. The release of the drug is 
proportional to the amount of drug remaining in its interior so that the amount of 
drug release by unit of time diminishes 
6.9.1.3 Higuchi model:  
 Drug release from the matrix devices by diffusion has been described by 
following higuchis classical diffusion equation. 
  Q = [DE/ τ(2A- ECs) Cst ]              eq( 3) 
Where 
Q   =   Amount of drug release at time t 
D   =   Diffusion coefficient of the drug in the matrix 
A    =   Total amount of drug in unit volume of matrix 
Cs   =   The solubility of the drug in the matrix 
E     =   Porosity of the matrix 
T     =   Time in hrs at which q is the amount of drug is release 
                Equation-3 may be simplified if one assumes that D, Cs and A are 
constant.  Then equation-3 becomes 
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 Q    =    K t ½      eq (4) 
 When the data is plotted according to equation-4 i.e. cumulative drug 
release versus Square root of time yields a straight line, indicating that the drug was 
released by diffusion mechanism. The slope is equal to k. 
Use:  The relation can be used to describe the drug dissolution from several types of 
modified release pharmaceutical dosage forms, as in case of some water soluble 
drugs. 
6.9.1.4 Korsmeyer Peppas model:      
 In order to understand the mode of release of drug from swellable 
matrices, the data were fitted to the following equation   
 Mt    /    Mά         = Kt
n    
eq (5) 
Where, 
       Mt / Mά         =      The fraction of drug released at time‗t‘ 
       K               =      Constant incorporating the structural and geometrical 
                                  Characteristics of the drug / polymer system. 
       n               =      Diffusion exponent related to the mechanism of release. 
The above equation can be simplified by applying log on both sides we get  
 Log       Mt  /   Mά             =     Log K+ n Log t        eq (6) 
 When the data is plotted as a log of drug released versus log time, yields a 
straight line with a slope equal to n and the k can be obtained from y- intercept. 
 The value of n for a cylinder is <0.45 for fickian release,  > 0.45 and < 
0.89 for non-Fickian release, 0.89 for the case 2 release and > 0.89 for  super case2 
type release. 
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6.9.2 Similarity Factor and Difference Factor Calculation 
 The similarity factor (f2) was defined by CDER, FDA, and EMEA as the 
―logarithmic reciprocal square root transformation of one plus the mean squared 
difference in percent dissolved between the test and Ditropan release profiles‖. 
 Dissimilarity or difference factor (f1) describes the relative error between 
two dissolution profiles. It approximates the percent error between the curves. The 
percent error is zero when the test and Ditropan release profiles are identical and 
increases proportionally with the dissimilarity between the two profiles. 
 There are several methods for dissolution profile comparison. f2 is the 
simplest among those methods. Moore & Flanner proposed a model independent 
mathematical approach to compare the dissolution profile using two factors f1 & f2. 
 f1 = { [  t=1 
nRt – Tt  ] / [  t=1 
n
 Rt ] } . 100  eq (1) 
 f2 = 50. Log { [1 + (1/n)  t=1 
n
 (Rt - Tt ) 
2
 ] 
–0.5 
. 100}  eq (2) 
 Where 'Rt' and ‗Tt' are the cumulative percentage dissolved at each of the 
selected n time point of the Ditropan & test product respectively. The factor f1 is 
proportional to the average difference between the two profiles, where as factor f2 is 
inversely proportional to the averaged squared difference between the two profiles, 
with emphasis on the larger difference among all the time points. The similarity 
factor f2 and its significance is shown in the following. 
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Table: 16 Similarity factor f2 and its significance 
S. No. Similarity factor  (f2) Significance 
1. <50 Test and Ditropan profiles are dissimilar. 
2. 50 -100 Test and Ditropan profiles are similar. 
3. 100 Test and Ditropan profiles are identical. 
4. >100 The equation yields a negative value. 
 
6.9.3   Stability Study:
 76-78.
 
 For all the pharmaceutical dosage forms it is important to determine the 
stability of the dosage form. This will include storage at exaggerated temperature 
conditions, with the necessary extrapolations to ensure the product will, over its 
designed shelf life, provide medication for absorption at the same rate as when 
originally formulated. Specification which is list of tests, reference to the analytical 
procedures and proposed acceptance criteria, including the concept of different 
acceptable criteria for release and shelf life specifications, is addressed in ICH 
guidelines. 
Storage Conditions 
 In general, a drug product should be evaluated under storage condition 
that tests its stability and if applicable, its sensitivity to moisture or potential for 
solvent loss. The long term testing should cover a minimum of 12 months study or at 
least three batches at the time of submission and should be continued for a period of 
sufficient time till it covers the proposed shelf life.  
 
 
 
  
 
Chapter 7 
Results 
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Preformulation : 
API characterization: 
 Initial weight of API taken   = 20 gm 
                Initial volume of API taken = 65 ml 
                Volume after 500 tap            = 47 ml 
                 Volume after 750 tap            = 47 ml 
Table: 17 Analysis of physical properties of Oxybutynin Hydrochloride 
Parameter Value Unit 
LOD 1.5 % w/w 
BD 0.198 gm/ml 
TD 0.353 gm/ml 
CI 43.75 % 
HR 1.78 ---- 
Angle of repose 32.3 ºc 
 
Sieve Analysis: 
 The procedure involves the Electromagnetic Sieve shaking of the sample 
through the series of successively arranged sieves (sieve no. , 40, 60, 80,100,120 and 
pan weight), and weighing of the portion of the sample retained on each sieve and 
calculate percentage retained on each sieve. 
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Table: 18 Results of sieve analysis of Oxybutynin Hydrochloride 
  Sieves 
Initial 
weight 
Final 
Weight 
Difference 
weight(gms) 
Retained 
Percentage 
Cumulative 
Percentage 
#40 162.5 162.5 0 0 0 
#60 167.5 167.5 0 0 0 
#80 166.0 167.0 1.0 2 2 
#100 152.0 154.0 2.0 4 6 
#120 149.5 152.5 2.0 4 10 
#Pan 142.0 168.0 26.0 52 100 
 
Drug excipient compatibility studies: 
 The compatibility of drug and formulation components is important 
prerequisite before formulation. It is therefore necessary to confirm that the drug 
does not react with the polymers and excipients under experimental conditions and 
affect the shelf life of product or any other unwanted effects on the formulation. 
Procedure: 
 Drug is mixed with excipients in different ratio. These mixtures were kept 
in a glass amber colored vials and packed properly. These vials are exposed to 40˚c / 
75 % RH. Observations for physical appearance are made at initially, 2 week, and 
4week, the samples were withdrawn for analysis of following parameter: 
1. Appearance 
2. IR Spectra 
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Table: 19 Differnet ratios of Drug and excipient taken for Compatibility Study 
Name of the 
Excipients 
Ratio 
 
Initial 
Final observation 
Conclusion 40 ° C / 75 % RH 
2
nd
 week 4
th
 week 
Oxybutynin chloride  
White to 
off  white 
White to 
off white 
White to 
off  white 
Compatible 
Oxybutynin chloride: 
Methocel k100M  
1:1 
White to 
off  white 
White to 
off  white 
White to 
off  white 
Compatible 
Oxybutynin chloride: 
Kollidon90F 
1:1 white White white Compatible 
Oxybutynin chloride: 
(avicel101) 
1:1 white White White Compatible 
Oxybutynin chloride: 
LubritabL30D55 
1:1 white White White Compatible 
Oxybutyninchloride: 
Tri ethyl Citrate 
1:1 white White White Compatible 
Oxybutynin chloride: 
Isopropyl alcohol 
1:1 white White white Compatible 
Oxybutynin chloride: 
Magnesium Stearate 
1:1 white White White Compatible 
Oxybutynin chloride: 
opadry white 
1:1 white White white Compatible 
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Fig : 9  FTIR  Spectra of Oxybutynin Hydrochloride prepared formulation 
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Fig: 10FTIR Spectra of Oxybutynin Hydrochloride pure drug. 
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Table: 20  Data for Standard plot of the Oxybutynin chloride using 6.8 pH 
Phosphate buffer 
S.No Concentration (µg/ml) Absorbance (nm) 
1 0 0.000 
2 1 0.076 
3 2 0.158 
4 3 0.228 
5 4 0.308 
 
 
Fig: 11 Standard plot of the Oxybutynin Hydrochloride using using 6.8 pH 
Phosphate buffer at 210mn. 
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Table: 21  Data for Standard plot for Oxybutynin Hydrochloride 
using 0.1M HCl  
S.No Concentration (µg/ml) Absorbance (nm) 
1 0 0.000 
2 1 0.082 
3 2 0.166 
4 3 0.248 
5 4 0.339 
 
          
Fig: 12 Standard plot of Oxybutynin chlorideusing using 0.1N HCl at 210mn 
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Analysis of Ditropan (innovator) details: 
      With the help of analysis of the Ditropan we will able to compare the 
results obtained of our formulated product and it may helpful for calculation of the 
(f2) similarity dissolution factor. 
 Analysis of the Ditropan was carried out for various physical parameters 
and In-vitro dissolution profile. 
 Description. 
 Thickness  
 Weight Variation  
 in vitro dissolution  
 
Table: 22   Details of Ditropan  
Generic name Oxybutynin Chloride Sodium 
Brand name DitropanXL, Protonix 
Manufactured and marketed  by Alza pharma 
Strength 15 mg 
Dosage form Osmotic pump 
Shape Oval 
Dimension 11.66 mm 
Imprinting ‗P 40‘  printed on one side 
Average Weight 200- 206 mg 
Storage Conditions 
 
Store at 25° C excursions permitted  
(15-30°C) protect from moisture. 
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Determination of flow properties: 
Table: 23  Formulation Parameters of formulated physical mixtures of drug 
and excipients. 
Formulation 
Blend  Characterization 
B.D  (gm/ml) T.D  (gm/ml) C.I (%) H.R 
F1 0.69 ± 0.06 0.94 ± 0.012 26.59 ± 0.04 1.3 ± 0.04 
F2 0.68 ± 0.07 0.84 ± 0.014 19.04 ± 0.04 1.32 ± 0.03 
F3 0.582 ± 0.08 0.86 ± 0.010 20.93 ± 0.04 1.31 ± 0.06 
F4 0.64 ± 0.06 0.79 ± 0.014 18.98 ± 0  .06 1.27 ± 0.04 
F5 0.57 ± 0.08 0.78 ± 0.012 16.66 ± 0.04 1.29 ± 0.08 
F6 0.59 ± 0.08 0.80 ± 0.014 20.00 ± 0.04 1.35 ± 0.06 
F7 0.571 ± 0.04 0.785±0.012 27.27 ± 0.06 1.35 ± 0.08 
F8 0.587 ± 0.04 0.792±0.012 19.883 ± 0.02 1.34 ± 0.04 
F9 0.584 ± 0.02 0.781±0.014 20.224 ± 0.03 1.33 ± 0.04 
 
Table: 24  Various Physical Properties of Oxybutynin Hydrochloride core 
Tablets 
Formulations Weight variation Hardnes Thicknes Friability %drug content 
F1 200  ±0.56 8.4±0.12 4.42±0.016 0.21±.008 102.3 
F2 200  ±0.65 10.5±0.14 4.43 ±0.012 0.160±0.06 103 
F3 200 ± 0.58 11.7±0.12 4.45±0.015 0.015±0.008 98 
F4 200 ± 0.62 13.6±0.16 4.47 ± 0.013 0.014±0.04 100.6 
F5 200 ± 0.35 13.7±0.14 4.43 ± 0.014 0.018±0.005 101.7 
F6 200 ± 0.68 13.8±0.15 4.42 ± 0.012 0.021±0.07 104.6 
F7 200 ±0.65 12.6±0.15 4.47 ± 0.015 0.010±0.09 101.7 
F8 200 ± 0.50 13.0±0.16 4.46 ± 0.014 0.018±0.008 102.1 
F9 200 ± 0.54 13.6±0.13 4.46 ± 0.016 0.0170±0.007 104.6 
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Table: 25  Physical Properties of Oxybutynin Hydrochloride Enteric coated 
Tablets: 
Formulations Weight variation 
F1 204.73 ± 0.25 
F2 205.61 ± 0.45 
F3 204.72 ± 0.29 
F4 203.71 ± 0.69 
F5 205.12 ± 0.79 
F6 204.09 ± 0.85 
F7 205.18 ± 0.55 
F8 204.21 ± 0.65 
F9 205.65 ± 0.30 
 
Table: 26 Acid resistance test for Oxybutynin Hydrochloride ER Tablets 
                For 2 hours in 0.1M HCl 
S.No %Enteric coating Dissolution in 0.1N Hcl Remarks 
F1. 2.25 Fail Tablet opened 
F2. 2.25 Fail Tablet opened 
F3. 2.25 Fail Tablet opened 
F4. 4.5 Pass Tablet remain intact 
F5. 4.5 Pass Tablet remain intact 
F6. 4.5 Pass Tablet remain intact 
F7. 4.5 Pass Tablet remain intact 
F8. 4.5 Pass Tablet remain intact 
F9 4.5 Pass Tablet remain intact 
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  In vitro dissolution Studies: 
Table: 27 in vitro dissolution profile for the Ditropan . 
Percentage  cumulative drug release 
Time 
(hrs) 
limits Unit 1 Unit 2 Unit 3 Unit 4 Unit 5 Unit 6 Average 
2 0-10% 5 7 4 5 5 5 5±0.98 
4 10-30% 24 27 25 26 24 23 24±1.47 
8 35-65% 47 49 48 47 45 47 47±1.32 
12  70 71 69 68 65 69 68±2.06 
16 
NLT-
75% 
81 79 78 75 78 79 79±1.96 
24  97 96 95 94 96 94 95±1.21 
               n = 6 
 
Fig: 13 In vitro dissolution profile for the Ditropan. 
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Table: 28  Comparative in vitro dissolution profiles for the formulation F1 
with Ditropan. 
Percentage  cumulative drug release 
Time 
(hrs) 
limits Ref Unit1 Unit 2 Unit 3 Unit 4 Unit 5 
Unit 
6 
Average 
2 0-10% 5 1 2 1 1 1 2 1.57±0.5 
4 10-30% 24 8 9 8 9 9 7 8.33±0.8 
8 35-65% 47 15 16 14 12 17 12 13.66±2 
12  68 23 21 23 22 26 21 23±1.86 
16 NLT-75% 79 54 52 54 52 55 52 53.16±13 
24  95 73 71 73 74 75 72    72±1.4 
                n = 6 
 
 
Fig: 14 Comparative in vitro dissolution profile for the formulation F1 with 
Ditropan 
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Table: 29 Comparative in vitro dissolution profile of F2 with Ditropan. 
Percentage  cumulative drug release 
Time 
(hrs) 
limits Ref Unit 1 Unit 2 Unit 3 Unit 4 Unit 5 Unit 6 Average 
2 0-10% 5 1 2 1 3 2 4 2.1±1.6 
4 10-30% 24 10 9 12 13 11 10 11±1.3 
8 35-65% 47 24 22 25 26 20 22 23±2.0 
12  68 33 31 33 32 31 34 32.3±1.1 
16 NLT75% 79 58 57 53 60 61 57 59±2.6 
24  95 77 78 76 80 79 81 79.5±1.7 
                 n = 6
  
      
Fig: 15 Comparative in vitro dissolution profile of F2 with Ditropan 
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Table: 30 Comparative in vitro dissolution profiles for the formulation F3 with 
Ditropan 
                          Percentage  cumulative drug release 
Time 
(hrs) 
limits Ref Unit 1 Unit 2 Unit 3 Unit 4 Unit 5 Unit 6 Average 
2 0-10% 5 1 2 1 1 2 2 1.57±0.5 
4 10-30% 24 9 7 10 9 7 8 8.12±1.10 
8 35-65% 47 21 24 23 21 22 21 22.14±1.15 
12  68 33 31 33 32 31 32 32±0.81 
16 NLT-75% 79 54 55 53 56 50 52 53.33±1.97 
24  95 77 72 74 72 71 73 73.16±1.95 
             n = 6 
 
Fig: 16 Comparative in vitro dissolution profile of F2 with Ditropan 
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Table: 31 Comparative in vitro dissolution profile for the formulation F4 with 
Ditropan 
Percentage  cumulative drug release 
Time 
(hrs) 
limits Ref Unit 1 Unit 2 Unit 3 Unit 4 Unit 5 Unit 6 Average 
2 0-10% 5 3 2 1 1 2 2 2±0.69 
4 10-30% 24 13 10 11 12 13 9 11.2±1.49 
8 35-65% 47 26 24 24 25 22 27 26±1.67 
12  68 33 31 33 32 31 32 37.71±2.3 
16 NLT-75% 79 58 59 60 60 57 57 57.83±1.2 
24  95 81 76 80 78 79 77 78.5±2.5 
              n = 6 
 
Fig: 17 Comparative in vitro dissolution profile for the formulation F4 with 
Ditropan 
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Table: 32  Comparative in vitro dissolution profiles for the formulation F5 
with Ditropan 
                                 Percentage  cumulative drug release 
Time 
(hrs) 
limits Ref Unit 1 Unit 2 Unit 3 Unit 4 Unit 5 Unit 6 Average 
2 0-10% 5 3 2 3 2 4 2 2.71±0.74 
4 10-30% 24 15 16 17 16 19 16 16.5±1.25 
8 35-65% 47 31 36 34 33 34 36 34±1.73 
12  68 46 50 49 46 47 48 47.66±1.49 
16 NLT75% 79 62 64 65 65 65 65 64.3±1.10 
24  95 81 79 81 83 84 83 81.83±1.67 
                   n = 6 
 
Fig:18 Comparative in vitro dissolution profile for the formulation F5 with 
Ditropan 
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Table: 33     Comparative in vitro dissolution profile for the formulation F6 with 
Ditropan 
Percentage  cumulative drug release 
Time 
(hrs) 
limits Ref Unit 1 Unit 2 Unit 3 Unit 4 Unit 5 Unit 6 Average 
2 0-10% 5 5 3 3 4 4 5 3.87±0.81 
4 10-30% 24 20 22 23 24 23 22 20.74±1.38 
8 35-65% 47 47 45 46 47 44 45 45.66±1.10 
12  68 60 63 64 62 59 62 61.6±1.69 
16 NLT-75% 79 72 70 72 73 74 74 72.6±1.38 
24  95 89 91 90 94 93 92 91.5±1.70 
            n = 6 
 
Fig:19 Comparative in vitro dissolution profile for the formulation F6 with 
Ditropan 
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Table: 34 Comparative in vitro dissolution profile for the formulation F7 with 
Ditropan 
Percentage  cumulative drug release 
Time 
(hrs) 
limits Ref Unit 1 Unit 2 Unit 3 Unit 4 Unit 5 Unit 6 Average 
2 0-10% 5 5 3 3 4 4 5 4±0.816 
4 10-30% 24 24 27 27 26 24 25 25.5±1.25 
8 35-65% 47 47 49 48 47 47 47 47.5±0.76 
12  68 70 69 67 65 68 71 68.3±1.97 
16 NLT-75% 79 75 74 73 69 71 74 74±2.11 
24  95 94 90 89 89 93 94 92±2.22 
             n = 6 
                  
      Fig: 20 Comparative in vitro dissolution profile for the formulation F7 
with Ditropan 
 
 97 
 
Table: 35  Comparative in vitro dissolution profile for the formulation F8 
with Ditropan 
                                  Percentage  cumulative drug release 
Time 
(hrs) 
limits Ref Unit 1 Unit 2 Unit 3 Unit 4 Unit 5 Unit 6 Average  
2 0-10% 5 4 7 6 7 6 7 6.8±1.09 
4 10-30% 24 26 27 28 26 27 25 26±0.97 
8 35-65% 47 47 49 48 47 47 47 49±0.95 
12  68 69 70 67 65 69 68 67±1.67 
16 NLT-75% 79 75 74 73 69 74 71 77±2.6 
24  95 94 97 95 96 97 98 96.1±1.34 
            n = 6 
 
Fig: 21 Comparative in vitro dissolution profile for the formulation F8 with 
Ditropan 
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Table:36 Comparative in vitro dissolution profile for the formulation F9 with 
Ditropan 
Percentage  cumulative drug release 
Time 
(hrs) 
limits Ref Unit 1 Unit 2 Unit 3 Unit 4 Unit 5 Unit 6 Average 
2 0-10% 5 5 7 6 7 5 5 5.75±0.89 
4 10-30% 24 24 27 27 26 24 25 25.5±1.25 
8 35-65% 47 47 49 48 47 47 47 47.5±0.76 
12  68 70 69 67 65 68 71 68.3±1.97 
16 NLT75% 79 75 74 73 69 71 74 76±2.41 
24  95 94 96 95 94 97 95 96±1.11 
             n = 6 
                  
Fig: 22 Comparative in vitro dissolution profile for the formulation F9 with 
Ditropan 
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Determination of release kinetics 
Table: 37 kinetic studies of matrix Tablets 
Release kinetics R
2
 Intercept slope 
Zero order 0.934 10.49 3.29 
First order 0.953 4.964 -0.14 
Higuchi 0.934 11.0 25.61 
Korsmeyer peppas 0.991 0.66 0.74 
                               
Dissolution- Zero Order kinetics 
 
 
Fig: 23 Graph for the formulation F8-Zero Order Kinetics 
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Dissolution- First order Kinetis 
 
 
Fig: 24 Graph for the formulation F8-First Order Kinetics 
 
Fig 25: Graph for the formulation F8-Higuchi model 
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Fig: 26 Graph for the formulation F8- Kors meyer Peppas model 
                   Difference Factor (f1) & Similarity Factor (f2) Calculation 
Table: 38   Difference Factor (f1) & Similarity Factor (f2) 
Difference Factor (f1) & Similarity Factor (f2) 
Time (t)  
[in Hours] 
Ditropan ® Test (T) 
Rt-Tt (Rt-Tt)² |Rt-Tt| 
   
2 5 6.8 -1.80 3.24 1.80 
4 24 26 -2.00 4.00 2.00 
8 47 49 -2.00 4.00 2.00 
12 68 67 1.00 1.00 1.00 
16 79 77 2.00 4.00 2.00 
24 95 96.17 -1.17 1.37 1.17 
Sum 318.00   17.61 9.97 
Number of Time points or intervals (Excluding Zero) 6 
Difference Factor - F1 [ Acceptance Criteria : 0 - 15] 3.14 
Similarity Factor - F2 [ Acceptance Criteria : 50 - 100] 85.13 
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Stability Studies: 
   Table: 39 Results for stability studies         
S.No. Tests Initial 1 Month 
1. Thickness (mm)  ± SD 4.5 ± 0.01 4.4 ± 0.11 
2. Diameter  (mm)  ± SD 4.2±0.02 4.2±0.03 
3. Hardness (kg/cm
2
) ± SD 12.2 ± 0.01 12.1 ± 0.1 
4. Friability (% W/W)   ± SD 0 0 
5. Weight variation (%)  ± SD 1.1 ± 0.12 1.0 ±0.3 
6. Drug content (% ± SD 99.50 ±.02 99.20 ± 0.03 
 
          The Stability studies on optimized formulation of Oxtbutynin 
hydrochloride extended release tablets were conducted according to the ICH 
guidelines. The various parameters tested during during studies of Oxtbutynin 
Hydrochloride extended release tablets are show in table. The formulation were 
withdrawn at suitable intervals (initial and 1 month) and analysed visually for 
physical appearance and evaluated for different tests. The tablets showed no visual 
differences and compiled with description. The percentage of drug release from the 
formulation F8 at different intervals of time is given in Table: 39 and was found to 
be matching with specification. From the above results, it can be concluded that the 
formulation F8 of Oxtbutynin Hydrochloride extended release tablets are stable. 
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Discussion  
8.1 Preformulation : 
 The experimental work started with the raw material analysis of 
Oxybutynin hydrochloride as per USP, the physical properties such as bulk density 
the tapped density, Carr‘s index, Hausner‘s ratio and angle of repose values were 
depicted in the Table: 17 
8.2 Drug Excipient- compatibility study:  
 The physical compatibility test between drug and excipients were carried 
out at 40º C ± 2 ºC/75 ± 5 % RH for 15 days and 30 days. The mixture does not 
show any visible change, thus indicating drug and other excipients do not have any 
physical incompatibility. 
          Fig: 9 Shows the FTIR spectra of plain Oxybutynin Hydrochloride and 
the Oxybutynin Hydrochloride formulation. 
The FTIR spectra of pure Oxybutynin Hydrochloride showed major band at 3328.89 
cm
-1 
for –OH stretch 1745cm-1 for C=O stretch, and 2928.71 cm-1 for CH2 
asymmetrical/symmetrical stretch. The Oxybutynin Hydrochloride in the physical 
mixture showed the major–band at 3337.4 cm-1 for OH stretching and 1742.50 cm-1 
for C=O and 239 or 1.74 for CH2. 
IR spectra of drug and excipients physical mixture shown in Fig: 10 also revealed 
that no considerable change was observed in bands of oxybutynin hydrochloride. 
Hence it indicates that the absence of interaction between the oxybutynin 
Hydrochloride and the polymer and excipients used in the formulation.   
 Standard calibration curve of oxybutynin hydrochloride in pH6.8 
phosphate buffer and 0.1 M HCl were derived from the concentration, and 
corresponding absorbance values. Linear regression analysis gave the equations for 
the line of best fit as Y =0.0765X, R
2=
0.9997 and Y=0.0884X, R
2=
0.9996 
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respectively. Linearity was observed in concentrations between1 to 5µg/ml. 
8.3 Preparation of Matrix tablet  
 Oxybutynin Hydrochloride is an anticholinergic which is used for the 
treatment of urinary incontinence. Because of its short half life attempts have been 
made to develop an extended release formulation to reduce the dosing frequency. 
HPMC K 100 M, a hydrophilic polymer with high viscosity, which when comes in 
contact with aqueous solutions hydrate and swells and forms a hydrogel matrix. 
Thus matrix formulation upon contact with gastric fluids swells and retards the 
release of Oxybutynin from the matrix. Pharmatose 200M and Avicel 102 were used 
as tablet diluents and their effect on the drug release was studied. 
 Eudragit L30D55 was used as enteric coating polymer which dissolves as 
pH above 5.5 to prevent the drug from degradation in the gastric pH. Different 
concentrations of EudragitL30D55 were studied.  
8.4 Evaluation of tablets   
  Bulk density, Tapped density, Carr‘s index, & Hausner‘s ratio were 
evaluated for the prepared blend, and the results showed in the Table: 23 indicate good 
flow property and compressibility. The physical parameters for core and enteric coated 
tablets like weight variation, thickness, hardness were evaluated. For core tablets the 
results were shown on Table: 24. 
8.4.1 Effect of HPMC K100M on drug release 
 in vitro dissolution study of the formulations F1& F2 containing 40% and 
35% of HPMC K 100M were prepared by direct compression method and compared, 
the flow of the blend from the hopper was not good and also the release from the 
formulations F1 & F2 were found to be 72% & 79% at the end of 24
th
 hour, which 
shows the release was not within the USP specified limit. A trail using Kollidon K 
90 F with different concentrations (2.5% and 10%) in combination with HPMC 
K100M for formulations F3 and F4, was done but the granules formed were very 
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fine and during compression spillage from the lower punch was observed and the 
release from the formulations at the end of 24
th
 hour was found to be 73% and 78% 
which are not complying with the specified limits. The release profiles for 
formulations were shown on Table: 30 &31, and fig: 16& 17. 
 Hence to meet the required release profile Oxybutynin hydrochloride, 
HPMC K100M , used alone to retard the release of the drug from the matrix 
formulation. Different prototypes F5, F6, F7 & F8 were developed using different 
concentrations of polymer (30%, 25%, 22.5% & 20%) respectively. The release 
from the formulation F8 containing 20% HPMC K 100M at 2
nd
, 4
th
, 8
th
, 12
th
, 
16
th
,and 24
th
 hrs was found to be 6.8%,26%,49%,67%,77% and 96% respectively. 
At the end of 24
th
 hour which is similar to that of similar to that of Ditropan. 
 When the concentration of the HPMC K 100M increased, the drug release 
was found to be decreased. Therefore, from formulations F1 to F8 different 
concentration of HPMC K100M showed different release profiles, of these 
formulations F8 observed to be followed USP specifications for extended release 
tablets. However, in order to confirm the effect of HPMC K100M on Oxybutynin 
Hydrochloride release, formulation F10 was prepared with 18% HPMC k100M(not 
shown in the formulation table),but the release was found higher (93%) at end of 
16
th
 hour. Therefore the polymer concentration optimized to be 20 % (F8).  
8.5 Acid resistance test: 
 Acid resistance test was performed to optimize the concentration of 
enteric coating polymer. Formulations F1, F2, and F3 coated with 4.5 mg were 
failed in the acid conditions and they have opened the layer in the Acid stage only. 
Hence, concentration of enteric coating was increased to 9 mg from formulations F4. 
The formulations remain intact in the acidic stage and opened only after entering 
alkaline pH only. The values for acid resistance were depicted in the Table: 26. 
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8.6 Release kinetic study for optimized matrix tablet: 
 The plot of cumulative percentage drug release as a function of time 
indicates that none of the formulation follows zero order or Higuchi Kinetics 
(Table: 37) the line of best fit obtained was first order release kinetics (R
2 
=0.956) 
and Korsmeyers Peppas model, the drug release data further analysed for curve 
fitting and the results (n=0.74) confirmed that the formulation followed non-Fickan 
(Anamalous) diffusion kinetics. 
8.7 Reproducibility batch 
  To check the reproducibility of batch, another batch of  F9 was prepared 
with the same formula of F8. The drug release at drug release at 2
nd
, 4
th
, 8
th
, 12
th
, 
16
th
, and 24
th 
hrs was found to be 5.75%, 25.5%, 47.5%, 68.3%, 76% and 96% 
respectively, for Oxybutynin hydrochloride. Hence the drug release from 
reproducibility batch (F9) was observed similar to that of optimized formulation. 
The results were shown in the Table: 36 & fig: 22. 
8.8 Comparision between optimized batch and Ditropan XL 
 The optimized batch (F8) was compared with the Ditropan. The drug 
release of optimized batch and the market product was found to be 96% and 95% at 
the end of 24
th
 hour. Table: 37 shows the formulation F-8 was seemed to be close to 
the Ditropan‘s release profile. Then similarity factor (f2) was calculated between 
formulation F-8 and Ditropan. Similarity factor was (85.13); therefore, formulation 
F-8 has similar release profile to the marketed formulation release. 
8.9 Stability batch 
 Stability studies were conducted for the formulations F8 and F9. The 
stability study was performed at 40
º
C /75 % RH for a specific time period. The 
tablets were analysed for appearance, weight variation, drug content and in vitro 
drug release. The overall results showed that the formulation is stable at the above 
mentioned. Storage conditions the results were depicted in Table: 39 
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       Summary 
 Chapter I begins with a general introduction presenting an overview of 
about extended release drug delivery systems.in the part of introduction the 
advantages, disadvantages, mechanism of extended release systems and matrix 
tablets were discussed thoroughly. 
 Existing literature reviewed in the chapter-II the review of literature 
carried out for selected drugs, polymer and design and evaluation of matrix tablets. 
  Chapter-III gives information on the selection of drugs and excipients, 
there by Oxybutynin hydrochloride is suitable candidate for extended release dosage 
form.  
 Chapter IV deals with the methodology followed for the preparation of 
matrix tablet after the raw material analysis and the Drug:excipient compatibility 
study. Ion for the preparation and evaluation of extended release matrix tablets of 
Oxybutynin hydrochloride. 
 Chapter V Includes the results of all the formulations .the drug excipient 
compatability study was done and found to have no interactions between oxybutynin 
hydrochloride and excipients, all the qualitative and quantative parameters were 
analyzed and tabulated. The plot of time versus percentage of drug was release was 
also given after the table the brief description about table and graph were also given 
for all formulations.   
   Precompressional parameters of matrix tablets (bulk density, tapped 
density, Carr‘s, index Hausner‘s ratio and angle of repose) are in the range of 
official standard, indicated that granules prepared by wet granulation method. The 
post compressional parameters of extended release tablets (hardness, friability, 
weight variation, thickness, and drug content), were with in the limits.  
 
 108 
 
in vitro dissolution profile of Extended release matrix tablets containing  oxybutynin 
Hydrichloride from  the formulation F8,  drug release at 2
nd
, 4
th
, 8
th
, 12
th
, 16
th
 and 
24
th
 hrs was found to be 6.8%, 26%, 49%, 67%, 77% and 96% respectively. 
 The kinetic of drug release for formulation F8 was calculated and plotted. 
The formulation F8 follows first order release kinetics and the drug release 
mechanism was found to be non-Fickan anomalous diffusion. 
 The optimized formulation was compared with marketed product and 
showed similar release profile. 
 Stabalitiy studies were conducted for the formulations F8 and F9.The 
stability study was performed at 40

C /75 % RH for a specific time period. The 
tablets were analysed for appearance, weight variation, drug content and in vitro 
drug release. The overall results showed that the formulation is stable at the above 
mentioned Storage conditions.  
     
                                                 
 
 
 
 
 
 
 
  
 
Chapter 10 
Conclusion 
 
 109 
 
        Conclusion 
 The oral extended release matrix tablet containing 15mg of Oxubutynin 
Hydrochloride provided extended release for 24 hours. The hydrophilic polymer 
HPMC K100M alone gave a satisfied release profile compared in combination with 
Kollidon K90 F. The optimized formulation followed first order kinetics while the 
drug release mechanism was non-Fickan (Anomalous type) controlled by diffusion 
through swollen matrix. 
 The optimized formulation F8 and the marketed formulation (Ditropan) 
were found to have a similar in vitro release profile, which is confirmed by f1 and f2 
values. 
 A month of stability study data revealed no marked changes in the 
physical parameters and drug release profile.     
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